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1. Zusammenfassung 
Typ-2-Diabetes ist gekennzeichnet durch Hyperglykämie, Insulinresistenz, reduzierte 
Insulinsekretion und β-Zellverlust, welcher mit einer Insel-Amyloid-Polypeptid- (IAPP) 
Aggregation in den Pankreasinseln einhergeht. Der Prozess der IAPP-Aggregation führt zur 
Bildung von IAPP-Oligomeren, die für β-Zellen zytotoxisch sind. Es gibt bislang keinen 
therapeutischen Ansatz, der auf die IAPP-Aggregation abzielt. Aus diesem Grund wurde der 
Antikörper NI-203.26C11 spezifisch gegen toxische humane IAPP-Oligomere entwickelt. In der 
Langzeitstudie wurde die Wirksamkeit einer wöchentlichen Behandlung mit NI-203.26C11 (0.3, 
1, 3, 10 mg/kg) im Vergleich zu zum inerten Antikörper LALA-PG NI-203.26C11 (10mg/kg) 
untersucht. Überraschenderweise hatten die transgenen Ratten im Alter von 11 Monaten noch 
keinen deutlich manifesten Diabetes entwickelt. Trotzdem zeigte sich tendenziell eine 
Verbesserung der Stoffwechsellage bei den mit NI-203.26C11 (1 bis 10mg/kg) behandelten 
Tieren. Die Therapie mit LALA-PG rNI.26C11 führte zu einem ähnlichen Ausmaß an Verlust der 
β-Zellfunktion wie das Vehikel, was bedeutet, dass die Makrophagenaktivierung ein wichtiger 
Wirkmechanismus für die Entfernung von zytotoxischen hIAPP-Oligomeren ist. Eine Methode 
zur Sichtbarmachung des sog. Target Engagement wurde unter Verwendung von unfixierten, 
gefrorenen Pankreasschnitten transgener Ratten erfolgreich entwickelt. Diese Methode ist ein 
wertvolles Werkzeug für die Visualisierung und Quantifizierung des NI-203.26C11-vermittelten 
Abbaus von IAPP-Aggregaten. Trotz den noch ausstehenden Ergebnissen zeigen unsere 
Untersuchungen, dass die Immuntherapie mit NI-203.26C11 in verschiedenen Tiermodellen 
umfassend validiert werden konnte und ein großes therapeutisches Potenzial zu besitzen scheint. 
 
Schlüsselwörter: Typ-2-Diabetes, HIP Ratten, Antikörpertherapie 
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2. Summary 
Type 2 diabetes is characterized by hyperglycemia, insulin resistance, reduced insulin secretion, 
and β-cell loss paralleled by islet amyloid polypeptide (IAPP) aggregation in pancreatic islets. 
The process of IAPP aggregation leads to the formation of IAPP oligomers, which are cytotoxic 
for β-cells. Up to date, there is no therapeutic approach targeting IAPP aggregation. For this 
reason, the antibody NI-203.26C11 targeting toxic human IAPP oligomers has been developed. 
In the long-term study, the efficacy of weekly treatment with NI-203.26C11 (0.3, 1, 3, 10 mg/kg) 
was assessed in comparison to the inert antibody LALA-PG NI-203.26C11 (10mg/kg). 
Surprisingly, at 11 months of age, the diabetic phenotype of transgenic rats had not yet 
progressed sufficiently to observe conclusive differences between treatment groups; however, the 
NI-203.26C11 (1 to 10mg/kg) treated rats seemed to show improved β-cell function. Therapy 
with LALA-PG rNI.26C11 resulted to similar loss of β-cell function as vehicle, implying that 
macrophage activation is a key mechanism of action for the clearance of cytotoxic hIAPP 
oligomers. A method of in vivo target engagement was successfully developed using unfixed 
frozen pancreas sections of transgenic rats. This will be a valuable tool for the visualization and 
quantification of NI-203.26C11-mediated clearance of IAPP aggregates. Despite some pending 
results, we believe that immunotherapy with NI-203.26C11 has been extensively validated in 
different animal models and holds great therapeutic potential. 
 
Keywords: type 2 diabetes, HIP rats, antibody therapy 
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3. Introduction 
3.1. Type 2 diabetes 
Type 2 diabetes (T2D) is a growing global health concern. An estimated worldwide prevalence of 
8.8% of adults (20 to 79 years of age) are suffering from diabetes, which corresponds to a total of 
424.9 million affected people. 90% of these cases are due to T2D, which is the most common 
form of diabetes. More importantly, a further increase is expected in the coming decades 
(International Diabetes Federation 2017). T2D is linked to both genetic and environmental risk 
factors (Tuomi et al. 2014). According to a recent review paper (Bellou et al. 2018), associated 
risk factors include dietary factors such as an increased consumption of processed meat, sugar-
sweetened beverages and decrease in whole grain consumption. There was also a positive 
correlation to obesity (which may be due to the overconsumption of the food items mentioned 
above) and physical inactivity as well as medical conditions such as the metabolic syndrome or 
gestational diabetes. Genetic and epigenetic factors also contribute to the manifestation of the 
pathological characteristics of T2D. Namely, these pathological characteristics of T2D are insulin 
resistance, defective insulin secretion, hyperglycemia, loss of β-cell mass and function, as well as 
micro- and macrovascular complications (Stumvoll et al. 2005; Despa et al. 2012) (Figure 1). 
 
 
 
Figure 1: Overview of the development of pathological changes and clinical complications during the progression of T2D 
(Piya et al. 2010). 
Another pathological characteristic is the formation of islet amyloid polypeptide (IAPP) -
aggregates in the islets of Langerhans (Stumvoll et al. 2005). Although IAPP aggregation is also 
seen to a lesser extent in healthy individuals (BELL 1959; Ludwig and Heitner 1967; Westermark 
1972), it is a typical morphological feature of T2D and can be observed in most of the people 
suffering from T2D (Westermark et al. 2011) (Figure 2).  
Introduction  
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Figure 2: Fluorescent β-cell immunostaining for insulin and IAPP aggregates in pancreatic islets of a health human and a 
human suffering from T2D in comparison. (Neurimmune AG) 
The pathological process of IAPP aggregation results in increased β-cell toxicity (Lorenzo et al. 
1994; Jurgens et al. 2011; Haataja et al. 2008; Abedini et al. 2016; Kahn et al. 1999; Jaikaran and 
Clark 2001; Clark and Nilsson 2004; Hull et al. 2004; Höppener and Lips 2006; Kapurniotu 
2001), which contributes to the pathogenesis of T2D. Despite extensive research concerning 
IAPP aggregation, many open questions remain. For example, the site of initiation, the triggering 
factors for amyloid formation and the exact mechanisms of cytotoxicity are still unclear.  
3.2. IAPP 
IAPP is also known as amylin. It is a 37-aa residue long peptide, which is co-secreted with 
insulin by pancreatic β-cells.  
Physiological role of IAPP 
Even though the physiological role of IAPP is still not fully understood, the known functions of 
the monomeric circulating peptide are diverse and involved in several important functions in the 
organism. High-affinity IAPP receptors are formed when receptor activity-modifying proteins 
(RAMPs) dimerize with the calcitonin core receptor (Muff et al. 1999; Tilakaratne et al. 2000). 
IAPP has an inhibitory effect on eating (Arnelo et al. 1996; Barth et al. 2003; Abedini et al. 2018; 
Lutz 2006; Lutz et al. 1994) and on gastric emptying (Reidelberger et al. 2001). Further, IAPP 
has been reported to inhibit glycogen synthesis and insulin-stimulated glucose uptake (Cooper et 
al. 1988) and to inhibit glucose transport (Zierath et al. 1992). The contradictory results regarding 
the impact of IAPP on insulin secretion indicate a possible dual effect. Further studies also 
indicate a paracrine or autocrine function of IAPP on pancreatic α-cells to reduce glucagon 
secretion. Overall, it is widely accepted that IAPP plays a fine-tuning role in metabolism and 
glucose homeostasis (Westermark et al. 2011). 
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IAPP sequence  
The phylogenetically well-preserved IAPP sequence indicates that these physiological functions 
are of importance (Westermark et al. 2011), yet there are minor but relevant variations between 
species. For example, human IAPP (hIAPP) and rodent IAPP (rIAPP) differ only by 6 of 37 
amino-acid residues (Figure 3). And yet, a high aggregation propensity has been observed in 
hIAPP in vitro (Kayed et al. 1999; Goldsbury et al. 2000; Padrick and Miranker 2001; Yanagi et 
al. 2011), while rIAPP has a much smaller propensity towards the formation of fibrils. Variation 
between species is most common in the 20-29 region of IAPP, 5 out of the 6 differences in 
amino-acid residues between hIAPP and rIAPP are found there. Proline residues in this region are 
also known as β-sheet breakers. They occur in rIAPP, but not in hIAPP (Westermark et al. 1990). 
The lack of these proline residues is strongly associated with amyloid formation. In this respect, it 
is interesting to note that feline IAPP is similar to hIAPP, and felines also develop diabetes 
mellitus similar to T2D (Betsholtz et al. 1989; Betsholtz et al. 1990). 
 
 
Figure 3: A comparison of the primary sequences of human IAPP (hIAPP) and rodent IAPP (rIAPP), with the six varying 
amino-acid residues (red) that are found in the amyloidogenic region (yellow).  
Amyloid diseases 
Amyloid is defined as highly ordered protein or peptide aggregation into cross-β-sheet structures 
(Sunde and Blake 1997; Greenwald and Riek 2010) in combination with deposited material such 
as proteoglycans and glycoprotein-serum-amyloid-P-component in vivo (Westermark et al. 
2007). T2D belongs to the group of amyloid diseases together with Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease and prion disease (Chiti and Dobson 2006, 2017). All 
of these diseases are caused by the aggregation of specific polypeptides, which are considered to 
be intrinsically disordered proteins (IDP) with no fixed 3D structure (Uversky et al. 2008). The 
failure to maintain a functional conformation can result in misfolding, loss of physiological 
function, aggregation and gain of toxic function (Uversky et al. 2009; Uversky 2010). Therefore, 
T2D has been proposed to belong to the protein misfolding diseases (Mukherjee et al. 2015). 
Process of hIAPP aggregation 
In pancreatic islets, hIAPP aggregation into amyloid fibrils occurs through an unknown 
mechanism (Abedini and Schmidt 2013; Cao et al. 2013; Westermark et al. 2011). New evidence 
suggests that it might be induced by a prion-like mechanism (Mukherjee et al. 2017). The 
aggregation of hIAPP can be divided into three stages (Figure 4a) (Abedini et al. 2016). In the lag 
phase (LP), prefibrillar oligomers are formed and aggregate further into amyloid fibrils during the 
growth phase (GP). In the saturation phase (SP), there is a balance between soluble hIAPP and 
amyloid fibrils. 
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a)                    b)  
 
   
Figure 4a) The 3 phases of amyloid formation: the lag phase, growth phase and saturation phase. The formation of 
cytotoxic oligomeric intermediates mainly occurs in the lag phase (Abedini et al. 2016) b) Viability of INS-1 β-cells in 
percentage after incubation with different IAPP species (early species, oligomers, mature fibrils) for 16 hours 
(Neurimmune AG). 
Toxic hIAPP oligomers 
The toxic oligomer hypothesis is supported by data showing that β-cell death is caused by 
prefibrillar toxic oligomers (Janson et al. 1999; Anguiano et al. 2002; Porat et al. 2003; Ritzel et 
al. 2007; Haataja et al. 2008; Abedini et al. 2016) rather than mature amyloid fibrils (Figure 4b). 
These toxic IAPP species are transient and form during the lag phase (LP) of amyloid formation. 
They induce oxidative stress, islet inflammation and β-cell apoptosis (Abedini et al. 2016). 
Interestingly, not all IAPP oligomers were found to be toxic. For example, the non-
amyloidogenic but non-toxic rIAPP also forms oligomers in vitro (Abedini et al. 2016; Young et 
al. 2014). The same was observed in point-mutated IAPP variants (Abedini et al. 2007; Meng et 
al. 2010; Wang and Raleigh 2014). This suggests that amino-acid sequence-dependent 
conformational properties determine cytotoxicity, rather than oligomer formation or size alone 
(Abedini et al. 2016). 
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Mechanisms of cytotoxicity 
The exact mechanisms of cytotoxicity are still unknown (Westermark et al. 2011; Akter et al. 
2016; Abedini and Schmidt 2013). Various studies suggest that β-cell toxicity can be caused by 
both intra- and extracellular hIAPP oligomers. Possible intracellular mechanisms of cytotoxicity 
include ER stress (Huang et al. 2007; Casas et al. 2007), mitochondrial membrane damage 
(Hernández et al. 2018) and defects in autophagy (Kim et al. 2014; Shigihara et al. 2014; Rivera 
et al. 2011). Extracellular mechanisms encompass various receptor-mediated mechanisms of 
cytotoxicity linked to oxidative stress (Zraika et al. 2009) and apoptosis (Abedini et al. 2018; 
Gurlo et al. 2016; Park et al. 2012), activation of the caspase cascade (Zhang et al. 2003) and 
direct membrane permeabilization and disruption (Gorbenko and Kinnunen 2006; Jayasinghe and 
Langen 2007; Brender et al. 2012; Gao and Winter 2015; Caillon et al. 2016; Engel 2009). 
Overall, multiple mechanisms of action may overlap, with possibly many more yet to be 
described (Abedini and Schmidt 2013). Despite all data indicating the implication of hIAPP in 
the T2D pathogenesis, there is no treatment targeting IAPP aggregation or protecting β-cells from 
IAPP-induced toxicity up to now (Ashcroft and Rorsman 2012; Halban et al. 2014) 
3.3.  Therapeutic approaches 
Current therapies mainly aim at lowering blood glucose, but there is no specific treatment 
available that can halt or reverse the progression of T2D by protecting β-cells (Ashcroft and 
Rorsman 2012; Halban et al. 2014). Therefore, the development of therapies preventing 
progressive β-cell loss is of utmost importance. This could be achieved by reducing inflammation 
or by activation of the unfolded protein response and autophagy that are impaired in T2D (Rojas 
et al. 2018). Another possible approach to preserve β-cells is to prevent cytotoxicity caused by 
the process of IAPP aggregation. Since this need has been recognized, numerous therapeutic 
approaches are being examined toward this aim. Extensive research is currently underway in this 
field, although conclusive clinical studies are still pending.  
Examples of therapeutic approaches 
There are many novel approaches concerning the development of compounds aiming at the 
inhibition hIAPP self-aggregation and neutralization of toxic oligomers. However, many of these 
studies have not surpassed in vitro experimentation. 
 
One approach is to develop compounds that inhibit hIAPP self-aggregation and neutralize the 
formation of toxic oligomers. This can be achieved through metal complexes, such as Co(III) 
(Lee et al. 2012), Cu(II) (Jeong et al. 2010), Al(III) (Xu et al. 2016), Schiff base oxovanadium 
(Xu et al. 2018) or titanocene complexes (Du et al. 2017).  
Chaperones, for example O4 (Zou et al. 2017), rutin (Aitken et al. 2017), serum amyloid A 
component (Gao et al. 2015), clusterin (Beeg et al. 2016), rationally designed Hsp70 
(Bongiovanni et al. 2018), polyphenols and their derivates such as EGCG (Franko et al. 2018; 
Ehrnhoefer et al. 2008; Xu et al. 2016) or curcumin (Pithadia et al. 2016; Sparks et al. 2012; 
Daval et al. 2010), as well as calcium-binding nuclebindin-1 (Bonito-Oliva et al. 2017), stabilize 
the structure of non-aggregated IAPP and thereby prevent aggregation. Short peptides such as 
macrocyclic peptides (Spanopoulou et al. 2018), hexa-peptides (Scrocchi et al. 2002), D-
ANFLVH (Wijesekara et al. 2015) and D-amino-acid (Wang et al. 2014) inhibit amyloidogenesis 
by mimicking IAPP interaction surface while possessing minimal elements of self- and cross-
recognition. To name a few further approaches, the use of nanoparticles (Guo et al. 2013; Yousaf 
et al. 2017), macromolecules (Seeliger et al. 2013), PEG-PE micelle (Fang et al. 2018), 
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dendrimers (Gurzov et al. 2016), siRNA (Marzban et al. 2016) and potentially even rIAPP (Cao 
et al. 2010) to prevent IAPP aggregation have been investigated. Interestingly, it has been 
proposed that certain amyloid inhibitors paradoxically prolong cytotoxicity by preventing further 
aggregation, therefore sustaining oligomer toxicity (Abedini et al. 2016). Other novel approaches 
are not only aimed at targeting aggregation but also at downstream mechanisms of hIAPP-
induced cytotoxicity, such as RAGE (Abedini et al. 2018). 
Immunotherapy 
Immunotherapy is another approach. An important aspect of immunotherapy is the ability of 
antibodies to both bind specifically to an antigen and to recruit immune effector functions (Wang 
et al. 2018). Due to their therapeutic potential for many disease complexes, over 70 antibodies 
underwent late-stage clinical trials within the last year (Strohl 2018). An increasing number of 
antibodies were approved for marketing within the last 4 years, reaching a new maximum of ten 
approvals in 2017 (Kaplon and Reichert 2018), with a tendency to rise even further.  
 
First studies examining immunotherapy targeting IAPP aggregates have been conducted. In 
transgenic hIAPP mice, a vaccination-based approach was found to be overall inconclusive (Lin 
et al. 2007; Krishnamurthy et al. 2016; Zhang et al. 2018). Also, specific antibodies against 
cytotoxic IAPP species have been identified in diabetic patients (Bram et al. 2014) and 
intravenous immunoglobin administration with polyclonal serum IgG was shown to have a 
protective effect on β-cells (Zhang et al. 2018). Despite these mixed results, the potential of 
immunotherapy against the toxic effects of hIAPP oligomers is commonly recognized. 
3.4. Parallels to Alzheimer research 
AD in general 
Alzheimer's Disease (AD) and T2D have many shared characteristics. AD is also a widely spread 
disease, as it is currently affecting 40 million people worldwide (Burns and Iliffe 2009; Prince et 
al. 2013; Prince et al. 2016), with a rising tendency. As in T2D, there is a long preclinical phase 
preceding the symptoms of AD (Villemagne et al. 2013). The hallmarks of AD are the misfolding 
and pathological aggregation of the peptide amyloid β (Aβ) in the brain and the aggregation of 
hyperphosphorylated protein tau intracellularly (Hardy and Selkoe 2002; Jack et al. 2010; 
Querfurth and LaFerla 2010). It has been suggested that toxic oligomers of protein misfolding 
diseases share many common features (Bolognesi et al. 2010; Bucciantini et al. 2002; Chen et al. 
2013; Chimon et al. 2007; Glabe 2008; Kim et al. 2009; Laganowsky et al. 2012; Mannini et al. 
2014), with Aβ possessing sharing a high similarity to hIAPP (Abedini et al. 2016). This 
similarity may even lead to cross-seeding behavior between the two amyloids (Andreetto 2010, 
Nicolls 2004, Zhang 2015). Furthermore, there is literature proposing other pathogenetic links 
between AD and T2D (Yang and Song 2013; Ninomiya 2014; Oskarsson et al. 2015).  
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AD and T2D 
Comparable to the situation in T2D, AD therapies only consist of symptomatic and transiently 
active treatments (Schilling et al. 2018). Hence, the interest in the successful development of 
passive immunotherapy against Aβ arose. One of these antibodies targeting Aβ aggregates is 
aducanumab, which has been shown to reduce amyloid load and preserve cognitive function 
repeatedly when chronically administered in AD patients. Aducanumab is a human-derived IgG1 
antibody identified by Neurimmune using its proprietary RTM technology platform, similarly to 
our antibody NI-203.26C11 targeting hIAPP aggregates for the treatment of T2D. The 
administration of aducanumab was associated with an increased recruitment of microglia, 
indicating induction of aggregated Aβ phagocytosis in preclinical models of AD. Additional 
mechanisms such as the neutralization of toxic oligomers are also being considered (Sevigny et 
al. 2016). Due to the pathological similarities between Aβ and hIAPP aggregates, it seems 
plausible that aducanumab and NI-203.26C11 antibody may share common mechanisms of action 
and disease-modifying properties. 
 
3.5. Previous studies using hIAPP directed antibodies 
The potential benefits of using antibodies against IAPP aggregates have been recognized in 
recent years and led to extensive research efforts. Even though antibody-based immunotherapy 
against IAPP aggregates has yet to be developed and validated, preliminary studies testing the 
antibody NI-203.26C11 have shown promising results. Upon extensive in vitro selection and 
validation, NI-203.26C11 targeting toxic hIAPP oligomers has been expressed recombinantly for 
in vivo testing in a set of preclinical studies in different animal models of T2D.  Among them, 
five studies have been conducted in hemizygous transgenic rats and mice (HIP rats and mice) 
expressing amyloidogenic hIAPP under the control of the rat II insulin promoter (Table 1).  
 
For studies in HIP rats, a chimeric version of the antibody NI-203.26C11 composed of rat IgG2b constant regions was 
administered intraperitoneally in weekly intervals, at doses ranging from 1 to 10 mg/kg and blood glucose levels and 
plasma insulin levels during oral glucose tolerance tests (OGTTs) have been measured at defined time points. Rat study 1 
showed improved glucose tolerance and insulin response in HIP rats treated with NI-203.26C11 (3mg/kg) compared to 
vehicle. In the second study, efficacy of rNI-203.26C11 (3 mg/kg) was evaluated for a longer time and compared to an IgG 
control (3 mg/kg). The results of study 1 confirmed rNI-203.26C11 efficacy, with reduced glycemia and β-cell loss. The aim 
of the third study was to determine the most effective dose of rNI-203.26C11 antibody. For this, three different doses (1, 3 
and 10 mg/kg) were applied to hemizygous HIP rats. Although the significant effect of the antibodies on slowing down the 
progression of T2D was reconfirmed, the 1 and 10 mg/kg doses were equally effective, with no clear dose-dependent effects 
observed. It was shown that rNI-203.26C11 protects pancreatic β-cells from hIAPP-induced toxicity (Figure 5). After 
weekly i.p. injections with rNI-203.26C11 (10 mg/kg) in transgenic HIP rats for 40 weeks, an increase in the insulin-
positive area as well as β-cell mass was observed. This protection resulted in the preservation of β-cell function, which was 
reflected by both improved insulin response and decreased blood glucose levels during an oral glucose tolerance test 
(OGTT;  
Figure 6). 
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Model Study 
Treatment Results of NI-203.26C11 treatment 
NI-203.26C11 
(weekly i.p.) 
Start Duration 
Improved 
glucose 
tolerance  
Improved 
insulin 
response* 
Reduced 
glycemia 
Reduced β-
cell loss 
HIP rat # 
1 
• 3 mg/kg (n=9) 
• vehicle (n=10) 
12 weeks of 
age 
18 weeks + + NA NA 
2 
• 3 mg/kg (n=11) 
• IgG (n=12) 
• vehicle (n=9) 
12 weeks of 
age 
30 weeks + + + + 
3 
• 1 mg/kg (n=19) 
• 3 mg/kg (n=17) 
• 10 mg/kg (n=18) 
• vehicle (n=18) 
12 weeks of 
age 
40 weeks + + + + 
4 
• 3 mg/kg (n=14) 
• metformin (n=14) 
• 3 
mg/kg+metformin 
(n=13) 
• 3 mg/kg backup 
AB (n=14)  
• vehicle (n=14) 
12 weeks of 
age 
33 weeks + + NA NA 
HIP mice 5 
• 10 mg/kg (n=22) 
• vehicle (n=25) 
4 weeks of 
age 
14 weeks + + + + 
Human islet- 
engrafted mice with 
HFD-induced 
diabetes 
6A 
• 10 mg/kg (n=6) 
• IgG (n=9) 
2 weeks post-
transplant 
12 weeks + + + NA 
6B 
• 10 mg/kg (n=3) 
• IgG (n=3) 
8 weeks post-
transplant 
6 weeks + + + NA 
Human islet- 
engrafted mice with 
STZ -induced 
diabetes 
7 
• 10 mg/kg (n=16) 
• IgG (n=14) 
at transplant 7-9 weeks ND ND + + 
Table 1: Overview of previous preclinical studies examining the effect of the antibody NI-203.26C11, with the animal model, study design, time and results. # Rats 
obtained from Charles River following embryo transfer and breeding; * Reflects β-cell function; NA = not applicable; ND = not determined (Neurimmune AG)
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Figure 5: a) Pancreatic islet of PBS- and rNI-20326C11-treated HIP rats using insulin immunostaining to visualize β-cells 
(1° guinea pig anti-insulin antibody and a 2° TRITC-labeled anti-guinea pig antibody); b) Percentage of insulin-positive 
pancreas area and β-cell mass in PBS- and rNI-20326C11-treated HIP rats (Neurimmune AG). 
 
 
 
Figure 6: Plasma insulin and blood glucose levels in an OGTT of the HIP rats study 3: significantly improved insulin 
response and glucose tolerance were observed at all timepoints of the OGTT (oral glucose tolerance test) in rNI-20326C11-
treated HIP rats compared to PBS-treated rats after 38 weeks of treatment. 
rNI-203.26C11 was also found to recruit macrophages in HIP rat islets. This was shown by 
pancreas histology with immunostaining of CD68-+ macrophages in pancreatic islets (Figure 7a), 
which illustrates an increase in macrophage infiltration. This increase in CD68+ islet area was 
quantified and found to be significant in islets from rNI-203.26C11-treated HIP rats compared to 
vehicle-treated rats (Figure 7b). 
  
b) 
 
a) 
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Figure 7: a) Pancreas histology of rNI-20326C11-treated HIP rats compared to vehicle-treated rats upon macrophage 
immunostaining (using bright field microscopy with 1° rabbit anti-CD68 antibody and 2°anti-rabbit antibody labelled 
with HRP (horse radish peroxidase); b) Quantification of CD68+ islet area in vehicle-treated HIP rats and rNI-20326C11-
treated HIP rats (Neurimmune AG).  
It has also been observed that NI-203.26C11 stimulates the uptake of hIAPP aggregates by 
human macrophages in vitro, suggesting antibody-mediated clearance of hIAPP aggregates by rat 
macrophages in vivo. This will be discussed in more detail in the next chapter (Inert LALA-PG 
rNI-203.26C11). This ability to both bind an antigen and simultaneously recruit immune effector 
functions is an important aspect of antibody therapy (Wang et al. 2018). Following this, rat study 
4 compared the lead antibody NI-203.26C11 to the first-line T2D medication metformin and to a 
slightly different back-up antibody (NI-203.11B12) selectively targeting hIAPP aggregates. NI-
203.26C11 was equally effective as metformin in reducing glucose intolerance and led to 
increased insulin release, suggesting improved β-cell function. NI-203.26C11 and NI-203.11B12 
antibodies were equally effective, confirming the pathological role of hIAPP aggregates. 
Together, these results from preclinical studies in HIP rats led to the conclusion that chronic 
treatment with NI-203.26C11 antibody protects β-cells. Additional studies performed in hIAPP 
transgenic mice and in human islet-engrafted diabetic mice showed consistent results to the rat 
studies. In conclusion, pre-clinical results obtained from different diabetic rodent models indicate 
that long-term administration of the antibody NI-203.26C11 may preserve β-cell function, 
resulting in improved glucose tolerance and insulin response. Results also demonstrate a disease-
modifying effect of NI-203.26C11 that slows down the progression of T2D. 
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3.6. Aims 
The overall aim of the current study was to investigate the following topics: 
 
1) The long-term effect of four different doses of NI-203.26C11 on β-cell function in 
glucose intolerant rats; 
2) The short-term effect of a single administration of NI-203.26C11 on β-cell function, drug 
and serum amylin levels in glucose intolerant and hyperglycemic rats; 
3) The role of macrophage-mediated clearance of hIAPP aggregates (using an inert and 
mutated LALA-PG version of NI-203.26C11 antibody); 
4) The development of a method for histological visualization and quantification of NI-
203.26C11-mediated clearance of hIAPP aggregates. 
Based on our previous dose response study (study 3), the minimal therapeutic dose remains 
unknown. We therefore repeated a dose-response study with weekly i.p. administration of 4 doses 
of the antibody NI-203.26C11 (0.3, 1, 3, 10 mg/kg). In addition, the short-term effect of a single 
i.p. administration of antibody NI-203.26C11 (10 mg/kg) on fasting blood glucose, plasma 
insulin, glucose tolerance and insulin response was examined over a course of 3 weeks. To 
examine whether NI-203.26C11 mediates clearance of toxic hIAPP aggregates, NI-203.26C11 
(10 mg/kg) efficacy was compared to an inert version (LALA-PG NI-203.26C11, 10mg/kg) in 
both the long- and short-term studies. LALA-PG NI-203.26C11 harbors three mutations in the 
Fcɣ domain preventing its interaction with Fcɣ-receptors on immune cells and immune responses 
(Lo et al. 2017). Therefore, the importance of macrophage activation and clearance of hIAPP 
aggregates was evaluated. The last aim was the development of a method for visualization and 
quantification of hIAPP clearance in vivo. Target engagement will be used as a mean to verify 
pharmacologically that NI-203.26C11 engages with pathogenic IAPP, enabling a correlation 
between target engagement and drug efficacy (Simon et al. 2013). 
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4. Material and methods 
4.1. NI-203.26C11 antibody 
The production of the antibody NI-203.26C11 was already described in detail previously 
(Hugentobler 2017). Neurimmune AG (Schlieren, Switzerland) developed the antibody which 
was used in this study through the following steps: human-derived monoclonal IgG1 antibodies 
produced by reactive memory β-cells were isolated from healthy elderly people and first screened 
by ELISA to identify antibodies selectively targeting pathological hIAPP aggregates. Selected 
antibodies were cloned using PCR and recombinantly produced in CHO (Chinese hamster ovary) 
cells. Selectivity of these recombinant antibodies toward pathological IAPP was further tested by 
ELISA, bio-layer interferometry and immunostaining on human diabetic and non-diabetic tissues. 
The lead candidate antibody NI-203.26C11 was chosen based on its high binding affinity (KD = 
1.5 ± 0.1 nM) and specificity to pathological hIAPP aggregates. While NI-203.26C11 
preferentially binds to pre-fibrillar hIAPP oligomers and to fibrils in a lesser extent, it does not 
recognize non-pathological IAPP species. This specificity results from binding a conformational 
epitope exclusively exposed on hIAPP aggregates. A chimeric rat version of NI-203.26C11 
antibody (rNI-203.26C11) was developed to minimize the immune response against the human 
part of the antibody using rat models. The rat chimeric antibody version is formed by combining 
the human IgG1 variable regions responsible for binding to the antigen, combined with rat IgG2b 
constant regions. The antibody NI-203.26C11 has an IgG-like PK profile with a t1/2 (half-life) of 
8 days in rats and mice. All antibodies were injected at a volume of 2 ml/kg. 
4.2. Inert LALA-PG rNI-203.26C11 
For this study, an inert variant of the rNI-203.26C11 antibody was produced to examine the 
mechanism of action more closely. The Fc-region of an antibody engages both humoral and 
cellular components of the immune system. This can result in complement-dependent 
cytotoxicity (CDC), antibody-dependent, cell-mediated cytotoxicity (ADCC), antibody-
dependent cellular phagocytosis (ADCP) and inflammation through cytokine secretion. These 
reactions can be prevented by using an inert variant of the antibody (Lo et al. 2017), in which 
interaction with the Fcγ-receptor is inhibited by point mutations in the Fc-region. For example, 
substituting the amino acids L234A, L235A (Chappel et al. 1991) and P329A (Idusogie et al. 
2001) residues leads to a “LALA-PG” variant of the antibody. This inert variant of the antibody 
cannot interact with Fcγ-receptors on the surface of immunocompetent cells, thus preventing an 
Fc-mediated immune response. Therefore, both complement-binding and antibody-dependent, 
cell-mediated cytotoxicity and activation of phagocytosis by macrophages are prevented, while 
maintaining the antibody’s characteristic pharmacokinetics and ability to bind to specific IAPP 
oligomers (Figure 8). This mechanism is translatable to human IgG1 (Schlothauer et al. 2016) 
and murine IgG2a (Lo et al. 2017) antibodies.  
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b) 
   
Figure 8: The binding properties of rNI-203.26C11 compared to LALA-PG rNI-203.26C11: a) binding profile of rNI-
203.26C11 (left) compared to LALA-PG rNI-203.26C11 (right) on the rat Fcγ-receptor CD64; b) Binding profile of rNI-
203.26C11 (left) and LALA-PG rNI-203.26C11 (right) to hIAPP aggregates (Neurimmune AG). 
4.3. Animal model 
Transgenic rats expressing hIAPP, also known as HIP or RIPHAT rats, were selected as the 
animal model for this study. The reason for this was the pathological similarities to human T2D 
in relation to islet amyloid aggregation and the loss of β-cells (approx. 50% at time of onset of 
diabetes). The spontaneous development and lifelong progression of diabetes in HIP rats 
correspond to those in humans suffering from T2D (Butler et al. 2004). After a prediabetic phase 
with impaired first phase insulin secretion and glucose intolerance, HIP rats develop diabetes 
between an age of 5-10 months, characterized by hyperglycemia and progressive hepatic and 
extrahepatic insulin resistance as well as hyperglucagonemia (Matveyenko and Butler 2006). 
 
As a control, wild-type rats of the same background were included. The genotype was determined 
by Charles River. Fasting blood glucose and plasma insulin levels of the transgenic (Tg) rats 
were compared to those of the wild type (WT) rats before and during the experiment to confirm a 
diabetic phenotype. Additionally, ThioS staining of amyloid deposits in pancreatic sections was 
also performed to confirm the genotype at the end of the study. Of the 85 Tg HIP rats ordered at 
Charles River, 7 were excluded from the study. 15 of the 14 WT rats that had been ordered were 
included in the study. 
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4.4. Animals and maintenance 
A total of 100 male rats were obtained from Charles River Laboratories (Wilmington, MA, USA) 
at an age of 8 weeks. Of these, 85 were hemizygous transgenic rats expressing hIAPP (Tg, 
Crl:CD (SD)) and 15 were wild type rats (WT, Cr:CD (SD)). 
Rats were kept under standardized living conditions consisting of a 12:12 hour light-dark cycle 
(light phase from 02:00 to 14:00) with an ambient temperature of 21 ±1°C degrees. They had ad 
libitum access to water and chow diet (Extrudate 3436, KLIBA NAFAG, Kaiseraugst, 
Switzerland) and were group-housed under enriched conditions in standard cages (Type 2000P, 
612x435x216mm). The health status of the facility was defined as conventional. The rats were 
given an acclimatization period of 4 weeks. The initial groups of up to six rats per transport cage 
were split into groups of 2-3 animals at the age of 13 weeks. At the age of 12 weeks, they were 
randomized into treatment groups based on their fasting glucose levels of the baseline OGTT. 
Rats were handled twice per week and subjected to a weekly health check and weighing.  
 
The Veterinary Office of the Canton of Zurich approved of all procedures involving the animals 
(license nr. 143-2015). The maximal expected degree of severity was 2. End-point criteria were 
defined as a weight loss > 20% or severe and lasting dehydration. In case of this severe diabetic 
phenotype or other unexpected suffering (for example self-mutilation, apathy, pain), euthanasia 
was performed by an overdose of pentobarbiturates (60mg/kg) followed by exsanguination. This 
occurred in 5 cases, which included a deep reaching open tail wound, dyspnea and three cases of 
severe weight loss. These animals were excluded from analysis. Two additional animals were 
excluded from the experiments due to misgenotyping by the commercial provider. No 
spontaneous deaths occurred up to the time point where this dissertation was written.  
4.5. Study design 
Two main experiments were performed. After an initial baseline OGTT (12 weeks of age), a dose 
response (DR) study was conducted for a total time span of 32 weeks to confirm dose-dependent 
efficacy. In this time span, a total of 7 OGTTs were performed. Additionally, an inert rNI-
203.26C11 antibody (LALA-PG) was tested with the aim to shed light on a possible mechanism 
of action involving macrophage activation and clearance of hIAPP aggregates by phagocytosis. 
After the DR study, a study on the pharmacokinetic and pharmacodynamic (PK/PD) profile of the 
antibody rNI-203.26C11 was planned over 3 weeks, including an additional OGTT; however, the 
latter study could not be performed before the writing of this dissertation due to some delays in 
the DR study. Nonetheless, the concept of the PK/PD study will be described below. Common 
factors of these two studies are the animals, which are reused partially, the tested antibodies (rNI-
203.26C11 and LALA-PG) as well as other parts of the methodology. 
DR study. The aim of the dose response (DR) study was to determine to which extent the effects 
of the antibody treatment differ between four dosages of rNI-203.26C11 (0.3, 1, 3, 10 mg/kg) 
compared to PBS and the inert LALA-PG rNI-203.26C11 antibody (10 mg/kg).  
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Figure 9: Timeline of the dose response (DR) study including the initial baseline OGTT (dark green) as well as the seven 
OGTTs (light green) every 3 to 6 weeks. The area in gray represents the future OGTT, as the DR was prolonged beyond 
the phase described in this thesis. 
This study was conducted in 92 rats from an age of 12 weeks over a period of 32 weeks; the study 
was extended beyond that time point for up to 38 weeks (Figure 9), but here, we will only report 
results up to the 32 week time point. The 92 rats consisted of 14 WT and 78 Tg rats divided into 
7 treatment groups (Table 2). The Tg rats were divided into 6 groups for the testing of varying 
doses (0.3, 1, 3, 10 mg/kg) of rNI-203.26C11 antibody at and of the LALA-PG (10 mg/kg) 
compared to PBS vehicle. The WT group was also treated with PBS.  
 
Treatment groups Genotype Number of rats 
0.3mg/kg rNI-203.26C11 Tg 10 
1mg/kg rNI-203.26C11 Tg 10 
3mg/kg rNI-203.26C11 Tg 8 
10mg/kg rNI-203.26C11 Tg 8 
10mg/kg LALA-PG rNI-203.26C11 Tg 10 
PBS Tg 32 
PBS WT 14 
Table 2: Numbers and genotypes of rats per treatment groups in the DR study (Tg = transgenic, WT = wild type). 
All rats were subjected to weekly antibody or PBS injections (i.p.) from an age of 13 to 37 weeks. 
A baseline OGTT took place at 12 weeks of age followed by OGTTs performed with an interval 
of three to six weeks (weeks 4, 9, 14, 19, 25, 29 and 32 after treatment start). Blood samples were 
collected during the OGTTs to measure fasting blood glucose (FG), fasting plasma insulin (FI) 
and insulin response (IR) as well as fasting plasma IAPP levels (Table 3). 
Blood glucose and plasma insulin levels were measured at the baseline OGTT (-1 week) and 
during the following OGTTs at weeks 4, 9, 14, 19, 25 and 32 after treatment start. Baseline IAPP 
were measured at the baseline, 2nd, 4th, 5th and 7th OGTT. In the last OGTT that will not be 
reported here, where anti-drug response and drug levels will be determined (12 months of age). 
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 Baseline 
OGTT 
1st OGTT 2nd OGTT 3rd OGTT 4th OGTT 5th OGTT 6th OGTT 7th OGTT 
Weeks of 
age 
12 17 22 27 32 38 42 45 
Weeks of 
treatment 
-1 4 9 14 19 25 29 32 
Months 3.5 4.5 5.75 7 8 9 10 10.75 
Additional 
parameters 
FG, GR, FI, 
IR, baseline 
IAPP 
FG, GR, FI, 
IR 
FG, GR, FI, 
IR, baseline 
IAPP 
FG, 
GR(Ritzel 
and Butler 
2003, 2003, 
2003) 
FG, GR, 
baseline 
IAPP 
FG, GR, FI, 
IR, baseline 
IAPP 
FG, GR FG, GR, FI, 
IR, baseline 
IAPP 
Table 3: Overview of OGTTs, the corresponding age and weeks of treatment as well as the examined parameters. FG: 
fasting glucose; FI: fasting insulin; IR: insulin response., GR: glucose response. 
 
At the end of the DR study, the PBS-treated WT (n=14) and PBS-treated Tg (n=32) rats will be 
reused in the PK/PD study. The remaining animals will be sacrificed after the last OGTT (12 
months of age approximately) and used for histological assessment of amyloid load in the 
pancreas. 
PK/PD study 
This pharmacokinetics and -dynamics (PK/PD) study will focus on the acute effect of a single 
administration of rNI-203.26C11 (10 mg/kg) or LALA-PG (10 mg/kg) over the duration of 3 
weeks (Figure 10) in old rats (12 months of age) with a diabetic phenotype, characterized by 
glucose intolerance and hyperglycemia.  
 
 
Figure 10: Timeline of the pharmacokinetic and pharmacodynamic (PK/PD) study with a single i.p. administration of rNI-
203.26C11, LALA-PG rNI-203.26C11 or PBS, followed by repeated blood sampling (1d, 2d, 3d, 7d, 14d, 21d) and a final 
OGTT (*). 
The aim of this study is to determine the distribution of the rNI-203.26C11 (10 mg/kg) and 
LALA-PG (10 mg/kg) antibodies in plasma and their acute efficacy on physiological indicators 
of β-cell function such as blood glucose, plasma insulin and IAPP levels at different time points 
after a single i.p. injection in transgenic rats. rNI-203.26C11 (10 mg/kg) will be compared to 
LALA-PG rNI-203.26C11 (10 mg/kg) and PBS vehicle. A total of 32 animals will be included in 
the study, all of which were previously treated with PBS in the DR study (10 WT, 22 Tg). This 
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results in 7 to 10 rats per group (Table 4). In all groups, plasma samples will be taken before (0d) 
as well as at various time points after the single injection (1d, 2d, 3d, 7d, 14d, 21d). The rats will 
be allocated to the different treatment groups based on fasting blood glucose levels during the 8th 
OGTT performed at the end of the DR study. The PK/PD study is planned to take place directly 
after the DR study. 
 
Treatment groups Genotype Number of rats (n) 
rNI-203.26C11 (10mg/kg) Tg 7 
LALA-PG rNI-203.26C11 (10mg/kg) Tg 7 
PBS Tg 8 
PBS WT 10 
Table 4: Numbers and genotypes of rats allocated to the different treatment groups for the PK/PD study (Tg = transgenic, 
WT = wild type). 
4.6. Oral glucose tolerance test (OGTT) 
The aim of the OGTT was to evaluate glucose intolerance in rats, quantified by the clearance 
capability of ingested glucose. An initial baseline OGTT was performed in the DR study just 
before the first administration of antibodies, at an age of 12 weeks. Then, an OGTT was 
performed 7 times in a time interval of 3 to 6 weeks (ages 17, 22, 27, 32, 38, 42, 45 weeks).  
 
The same protocol was followed as described previously (Hugentobler 2017). After a 12h fasting 
period (19:00 to 07:00, of which the last 5h were in the light phase), 2 g/kg of glucose (50% 
glucose, B. Braun, Melsungen, Germany) was administered by oral gavage. Blood was collected 
from the sublingual vein (20G needle) upon brief anesthesia with isoflurane (3-4%, Attane, 
Piramal Enterprises Limited, Mumbai, India) to determine blood glucose levels prior to and 15, 
30, 60, 120 and 240 minutes after the glucose administration. Blood glucose levels were 
determined by Contour XT glucometer and glucose stripes (Contour, Bayer, Basel, Switzerland). 
Additional blood was collected in tubes (350 μl full blood/500 μl EDTA Microtainer K2E tube, 
Becton Dickinson, Franklin Lakes, USA) for plasma extraction to analyze plasma insulin (ELISA 
kit Mercodia 10-1250-01) and IAPP levels (MERCK-Millipore EZHA-52K).  
 
Anti-drug antibody and NI-203.26C11 levels will also be measured by ELISA in plasma samples 
from the last OGTT of the DR study and the PK/PD study. For the determination of anti-drug 
antibody levels, a Corning 3690 plate was coated with 10 µg/ml h26C11 in PBS O/N followed by 
incubation of a 1:5000 dilution of rat plasma, detection with rat IgG-specific and HRP-conjugated 
secondary antibodies (SouthernBiotech) and measurement of HRP activity using standard 
procedure. For determination of plasma levels of rNI-203.26C11 and LALA-PG rNI-203.26C11, 
the Corning 3690 plate was coated with 1 µg/ml of a previously validated anti-idiotypic Fab 
antibody generated by HuCAL technology and selectively recognizing NI-203.26C11 
(AbD23344.1, AbD Serotec) in PBS O/N RT. Non-specific binding sites were blocked for 1h at 
RT with a blocking buffer (2 % BSA, 0.1 % tween-20 in PBS buffer pH 7.4). Plasma samples 
were diluted 1:30’000 in PBS. Calibration samples were prepared similarly by diluting rNI-
203.26C11 antibody in PBS with a concentration range from 1.37 pM to 1 nM. Samples were 
then incubated for 1h at RT, and rNI-203.26C11 was detected with HRP-conjugated anti-rat 
IgG2b (gamma chain specific) and anti-rat kappa (kappa chain specific) secondary antibodies 
(SouthernBiotech) mixed at a 1:5000 dilution in PBS, followed by measurement of HRP activity 
using standard procedure.  
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The samples were analyzed using a SUNRISE plate reader (Firmware: 3.32 08/07/08; 
XFLUOR4(VERSION1) Version: 4.51) except for amylin, which was analyzed using a Thermo 
VARIOSCAN LUX plate reader. 
4.7. Target engagement 
A further aim was to visualize NI-203.26C11-mediated clearance of IAPP aggregates. Due to the 
transient nature of hIAPP oligomers targeted by NI-203.26C11 and their sensitivity to fixation, 
standard immunostaining approaches were not suitable for the tissue detection of IAPP 
aggregates using NI-203.26C11. Therefore, an alternative approach relying on in vivo target 
engagement was developed to visualize and quantify hIAPP aggregates recognized by NI-
203.26C11. The development of this method provides a useful tool for future research. 
 
Immunodetection of hIAPP aggregates has been achieved recently upon in vivo target 
engagement in HIP transgenic mice with a NI-203.26C11-derived fluorescently labeled diabody 
administered at 30 mg/kg i.p., followed by pancreas harvesting after 2 days and imaging of 
fluorescently labeled diabody on fixed frozen sections. A diabody is a fusion protein that consists 
of two dimerized single chain variable light and heavy chain fragments (Holliger et al. 1993). In 
this case, the diabody consisted of fragments of the variable regions of NI-203.26C11, resulting 
in similar binding properties compared to the parent antibody towards hIAPP aggregates (data not 
shown). In general, diabodies were shown to have a very high affinity (Adams et al. 1998). 
Tissue detection of the NI-203.26C11-derived diabody was combined with counterstaining using 
a commercial antibody towards physiological monomeric hIAPP. Specificity of the NI-
203.26C11-derived diabody toward aggregated hIAPP structures and absence of binding to 
monomeric hIAPP was shown (Figure 11). In the WT, no target engagement was observed. 
Unfortunately, for cost and practicality reasons, this fluorescently labeled diabody is not suitable 
for use in HIP rats, where a large amount would be required due to the higher body weight. 
Therefore, the aim was to develop a more suitable approach. 
 
 
Figure 11: Immunofluorescent staining of a pancreatic islet of a HIP mouse with a commercial anti-hIAPP antibody 
(green) and a NI-203.26C11-derived fluorescently labeled diabody (blue; Neurimmune AG). 
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For immunodetection of hIAPP aggregates by in vivo target engagement in HIP rats, human 
LALA-PG NI-203.26C11 antibody was administered at 30 mg/kg and rats were sacrificed 3 days 
post-injection. Rats were anesthetized using pentobarbital (60mg/kg i.p.). Then pancreas tissue 
was removed, immerged in 30% sucrose in PBS for a few hours until submersion, frozen in OCT 
(Tissue Freezing Medium, LEICA BIOSYSTEMS) and stored at -80°C. Frozen pancreas sections 
(5 µm) were incubated in blocking buffer (PBS + 5% serum (horse/goat) + 4% BSA) for 1h at 
RT, followed by incubation with Alexa488-conjugated anti-human secondary antibody (Jackson 
ImmunoResearch; 1:200) overnight at 4°C. Sections were counterstained with polyclonal guinea 
pig anti-insulin antibody (1:2; FLEX; Dako) and TRITC-conjugated goat anti-guinea pig 
secondary antibody (Jackson ImmunoResearch; 1:200). Slides were mounted using Hydromount 
media (National Diagnostics). Fluorescent slides were imaged using a VS120 slide scanner 
(Olympus Life Science). 
4.8. Quality control 
The quality was ensured at various time points by a broad range of measures. The study was 
blinded by assigning random variables (Q, T, V, W, Z for the DR study) to the treatment groups, 
while the PBS were defined as such. A lab book was kept, to ensure both reproducibility and 
traceability.  
4.9. Statistics 
For statistical analysis and graphical illustration of the data, GraphPad Prism 7 (La Jolla CA, 
USA) was used. For the analysis of the bodyweight, fasting glucose and insulin, glucose 
tolerance and insulin response, a two-way ANOVA with a Tukey’s multiple comparison test was 
used. Animals with missing values were excluded. The values of the WT and Tg rats in the 
baseline OGTT were compared using unpaired T-test assuming Gaussian distribution. The area 
under curve (AUC) of the groups was computed using a one-way ANOVA with a Tukey’s 
multiple comparison test and the group means, which calculated using the AUC of each 
individual animal at each timepoint. Significance was defined by a p-value of <0.05 and the data 
is presented as mean (M) ± standard error of mean (SEM).  
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5.   Results 
5.1. Animals  
Overall, no generalized polyuria and polydipsia (PU/PD) was observed in the Tg rats up to an age 
of 45 weeks. Individual animals developed a pronounced diabetic phenotype and a bodyweight 
loss of >20% at 43 weeks of age and had to be euthanized prematurely, i.e. after 30 weeks of 
treatment. The respective rats belonged to three different treatment groups (3mg/kg, 10mg/kg, 
PBS) and were excluded from the statistical analysis. No obvious difference was observed in the 
phenotype of the different treatment groups including the LALA-PG treated rats. As expected, no 
diabetic symptoms occurred in the WT rats. 
5.2. Body weight gain 
During the whole experiment, all rats were weighed weekly over a time span of 37 weeks. The 
body weight (BW) gain was compared between the treatment groups at all time points. Overall, 
the groups gained weight continually and only some animals lost weight occasionally or 
generally in the week following the OGTTs, respectively. There was a significant difference in 
BW (g) in the Tg PBS compared to the WT PBS rats from as early as 14 weeks of age. At 45 
weeks of age, the mean BW (g) of the Tg PBS rats was 13.5% lower compared to that of the WT 
rats (mean difference of 102.1g). 
 
  
 
Figure 12: BW gain (%) of the 7 groups in comparison over 37 weeks. The OGTTs are indicated with black grid lines, the 
start of the weekly antibody injections with a blue grid line. See legend of symbols for significant differences. 
Φ, ω, δ 
λ 
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Between the different Tg treatment groups and WT group, there was no difference in BW gain 
(%) up to 42 weeks of age (Figure 12). From week 42 onwards, there was a significant decrease 
in BW gain in the 0.3mg/kg, LALA-PG 10mg/kg and Tg PBS treated groups compared to the 
WT PBS. In the Tg PBS group, the decrease in BW gain progressed and became highly 
significant compared to the WT PBS group from 43 weeks of age on. In the 0.3mg/kg Tg group, 
the decrease in BW gain became highly significant compared to the WT PBS from 44 weeks of 
age onwards. In week 45, additionally, the 10mg/kg group showed a significant decrease in BW 
compared to the WT. 
5.3. Dose response study 
In total, 8 OGTTs were held in the DR study in rats aged between 12 and 45 weeks. The rats 
received weekly injections from 13 to 45 weeks of age, for a total of 32 weeks. The following 
symbols were used to express the significant differences between the groups (Table 5):  
 
 Tg PBS Tg 0.3mg/kg Tg 1mg/kg Tg 3mg/kg Tg 10mg/kg 
Tg LALA-
PG 10mg/kg 
Compared to 
WT PBS 
(Tg and WT) 
Φ δ ε χ λ ω 
Compared to 
Tg PBS 
(only Tg) 
- α η μ π * 
Quantity of symbols indicates grade of significance, for example: 
WT PBS vs. Tg PBS: Φ: p<0.05, ΦΦ: p<0.01, ΦΦΦ: p<0.001, ΦΦΦΦ: p<0.0001 
Table 5: Legends of symbols used for significant differences in graphs. 
Fasting glucose  
Fasting glucose (FG) was measured in each OGTT, starting with the baseline OGTT (12 weeks of 
age), up to the last OGTT (45 weeks of age, i.e. after 32 weeks of treatment). In the baseline 
OGTT, there was no difference between the WT and Tg rats. From the baseline OGTT to the 3rd 
OGTT after the start of treatment, no significant differences were observed between the Tg 
treatment groups and the WT group. From the 4th up the 7th OGTT, the 0.3mg/kg, LALA-PG 
10mg/kg and PBS Tg groups showed a highly significantly increase in FG compared to the WT 
PBS. In addition, the 3mg/kg group had a significantly increased FG in the 4th OGTT and the 
1mg/kg group in the 6th OGTT compared to WT PBS. Within the treatment groups, no consistent 
significant changes were observed. The 10mg/kg group had significantly lower FG levels than the 
Tg PBS and LALA-PG groups in the 4th OGTT. In the 7th OGTT, the LALA-PG group had 
significantly higher FG levels than the Tg PBS and the 1mg/kg groups (Figure 13, Table 6). 
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Figure 13: FG (fasting glucose) levels in mmol/l over time measured before each of the eight OGTTs. See legend of 
symbols for significant differences. 
 
OGTT 
(WOT) 
WT  
(mmol/l) 
Tg PBS  
(mmol/l) 
Tg 0.3mg/kg 
(mmol/l) 
Tg 1mg/kg 
(mmol/l) 
Tg 3mg/kg 
(mmol/l) 
Tg 10mg/kg 
(mmol/l) 
Tg LALA-PG 
(mmol/l) 
Significance 
Baseline 6.41 ±0.16 7.04 ±0.15 6.93 ±0.34 6.77 ±0.17 6.66 ±0.38 7.01 ±0.35 7.25 ±0.24 - 
1
st 
(4) 7.41 ±0.15 8.10 ±0.17 7.89 ±0.21 7.43 ±0.08 7.66 ±0.29 7.85 ±0.34 7.99 ±0.17 - 
2
nd 
(9)
 
7.38 ±0.26 8.26 ±0.15 8.11 ±0.20 8.10 ±0.26 7.80 ±0.26 8.10 ±0.35 8.34 ±0.14 - 
3
rd 
(14)
 
7.61 ±0.31 8.47 ±0.23 7.96 ±0.29 7.81 ±0.24 8.50 ±0.25 7.45 ±0.18 8.43 ±0.25 - 
4
th 
(19)
 
6.84 ±0.16 8.75 ±0.28 8.43 ±0.40 7.96 ±0.35 8.70 ±0.41 7.45 ±0.43 9.54 ±0.56 π δδ χχχ ϕϕϕϕ ωωωω 
5
th (26) 6.38 ±0.12 7.66 ±0.17 7.86 ±0.29 7.51 ±0.22 7.49 ±0.24 7.31 ±0.19 7.95 ±0.23 δδ ωω ϕϕϕ 
6
th 
(29)
 
6.37 ±0.19 7.55 ±0.17 8.10 ±0.31 7.63 ±0.29 7.58 ±0.35 6.99 ±0.20 7.94 ±0.18 ε ωω ϕϕ δδδ 
7
th 
(32)
 
6.89 ±0.13 7.99 ±0.16 8.98 ±0.56 7.66 ±0.33 7.76 ±0.24 7.84 ±0.28 9.11 ±0.65 * ϕϕ δδδδ ωωωω 
Table 6: Means and standard error of means of fasting glucose (FG) in mmol/l of all groups in different OGTTs. See 
legend of symbols for significant differences. WOT= weeks of treatment. 
Fasting insulin 
The same samples were used to examine fasting insulin (FI) at the baseline (OGTT before start of 
treatment) as well as the 1st, 2nd, 5th and 7th OGTT. Overall, the WT PBS had higher FI levels 
than most of the Tg groups in all OGTTs, apart from the baseline OGTT. In the baseline OGTT, 
no differences could be seen between the FI of the WT and Tg rats. Overall, increased FI levels 
were observed in the WT rats compared to the Tg 0.3 and 3mg/kg groups as well as the Tg PBS 
group from the 1st OGTT onward. From the 2nd OGTT on, the LALA-PG group also had a 
decreased FI level compared to the WT PBS, the same occurred with the 10mg/kg group from the 
5th OGTT onwards. The 1mg/kg Tg group only had significantly decreased FI values compared to 
the WT PBS in the 2nd OGTT. Despite this, the FI levels between the different treatment groups 
remained comparable except for the last OGTT. There, the 0.3mg/kg treated group had 
significantly higher FI levels than the Tg PBS group (Figure 14, Table 7). 
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Figure 14: FI (fasting insulin) levels in μg/l over time measured at the baseline, 1st, 2nd, 5th and 7th OGTT (over 32 weeks). 
See legend of symbols for significant differences. 
 
OGTT (WOT) 
WT 
(μg/l) 
Tg PBS 
(μg/l) 
Tg 0.3mg/kg 
(μg/l) 
Tg 1mg/kg 
(μg/l) 
Tg 3mg/kg 
(μg/l) 
Tg 10mg/kg 
(μg/l) 
Tg LALA-PG 
(μg/l) 
Significance 
Baseline 0.16 ±0.01 0.15 ±0.01 0.13 ±0.00 0.16 ±0.01 0.12 ±0.01 0.15 ±0.01 0.14 ±0.01 - 
1st (4) 0.22 ±0.04 0.09 ±0.01 0.08 ±0.00 0.13 ±0.01 0.08 ±0.01 0.11 ±0.02 0.10 ±0.01 δ χ ϕϕ 
2nd (9) 0.43 ±0.06 0.26 ±0.01 0.25 ±0.01 0.29 ±0.02 0.25 ±0.02 0.30 ±0.01 0.26 ±0.01 ε δδ χχχ ωωω ϕϕϕϕ 
5th (29) 0.38 ±0.04 0.23 ±0.01 0.22 ±0.02 0.29 ±0.02 0.20 ±0.02 0.24 ±0.02 0.24 ±0.02 λ ω δδ χχ ϕϕϕ 
7th (32) 0.45 ±0.04 0.28 ±0.01 0.42 ±0.14 0.38 ±0.04 0.28 ±0.01 0.30 ±0.02 0.29 ±0.03 λ χ δδ ωω αα ϕϕϕϕ 
Table 7: Means and standard error of means of fasting insulin (FI) in μg/l of all groups of rats in different OGTTs. See 
legend of symbols for significant differences. WOT = weeks of treatment. 
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Glucose tolerance  
The glucose response was examined in all eight OGTTs. From as early on as the baseline OGTT 
onwards, the Tg rats had an impaired glucose tolerance compared to the WT rats (time points 30, 
60, 120 minutes). From the 1st to the 4th OGTT, the glucose levels of 3mg/kg group were 
significantly lower than those of the Tg PBS group in either the 30- or 60-minute time points, or 
both. Also, except for the 7th OGTT, a significant decrease in glucose levels was observed in the 
3mg/kg compared to the LALA-PG 10mg/kg group in all OGTTs at the 60- and/or 120-minute 
time points. In the last OGTT, no significant difference in glucose tolerance or in glucose AUC 
was seen at any time point between the Tg groups. Compared to the WT rats, all Tg groups 
showed significantly higher glucose levels at the 15-minute time point, except for the 3 and 
10mg/kg groups. All Tg groups had significantly higher glucose levels at the 30-, 60- and 120-
minute time points. At the 240-minute point, only the 0.3mg/kg and Tg PBS groups still had 
elevated glucose levels compare to the WT group (Table 8, Table 9Figure 15).  
 
Within the Tg rats, no difference was observed in the baseline glucose levels or AUC during the 
OGTT done at baseline. The glucose AUC of the 0.3mg/kg, LALA-PG 10mg/kg and Tg PBS 
groups was increased significantly compared to the WT PBS in all the OGTTs. From the 2nd 
OGTT on, the 1mg/kg group also had an increased glucose AUC compared to the WT PBS. The 
AUC glucose of the 10mg/kg group was increased only once compared to the WT PBS, namely 
in the 3rd OGTT. The AUC glucose of the 3mg/kg group was never increased significantly 
compared to the WT PBS (Table 9, Figure 16). 
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Figure 15: Comparison of glucose curves (mmol/l) at different time points in all OGTTs for each group. See legend of 
symbols for significant differences. 
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  (min) 
Tg 0.3mg/kg 
(mmol/l) 
Tg 1mg/kg 
(mmol/l) 
Tg 3mg/kg 
(mmol/l) 
Tg10mg/kg 
(mmol/l) 
Tg LALA-PG 
10mg/kg (mmol/l) 
Tg PBS 
(mmol/l) 
WT PBS 
(mmol/l) 
Significances 
baseline OGTT 
(-1 WOT) 
0 6.93 ±0.34 6.77 ±0.17 6.66 ±0.38 7.01 0.35 7.25 ±0.24 7.02 ±0.15 6.41 ±0.16 - 
15 11.24 ±0.27 11.14 ±0.32 11.04 ±0.30 10.78 0.35 11.41 ±0.22 11.16 ±0.19 10.67 ±0.13 - 
30 12.55 ±0.48 11.97 ±0.54 11.24 ±0.63 11.80 0.57 12.46 ±0.48 12.18 ±0.30 9.76 ±0.22 λλ εεε ωωωω δδδδ ϕϕϕϕ 
60 12.02 ±0.66 11.23 ±0.68 11.01 ±0.88 10.74 0.52 11.48 ±0.40 11.51 ±0.35 8.89 ±0.49 λ χχ μμ εεε ωωωω δδδδ ϕϕϕϕ 
120 9.18 ±0.36 9.36 ±0.41 9.33 ±0.39 9.41 0.28 9.43 ±0.36 9.59 ±0.28 8.18 ±0.16 ϕ 
240 8.19 ±0.32 8.64 ±0.24 7.96 ±0.25 8.61 0.25 8.26 ±0.13 8.25 ±0.14 7.85 ±0.11 - 
1
st
 OGTT 
(4 WOT) 
0 7.89 ±0.21 7.43 ±0.08 7.66 ±0.29 7.85 0.34 7.99 ±0.17 8.11 ±0.16 7.41 ±0.15 - 
15 11.77 ±0.39 11.19 ±0.28 11.13 ±0.24 10.99 0.33 11.82 ±0.28 11.83 ±0.23 10.36 ±0.16 ϕ 
30 12.36 ±0.54 12.10 ±0.52 11.21 ±0.48 11.59 0.44 12.30 ±0.25 12.69 ±0.36 10.75 ±1.02 ϕϕ 
60 11.82 ±0.78 11.24 ±0.77 9.39 ±0.55 10.39 0.48 11.78 ±0.45 11.72 ±0.53 8.64 ±0.35 μ εεε δδδδ ωωωω ϕϕϕϕ 
120 9.41 ±0.46 8.73 ±0.38 8.44 ±0.27 8.75 0.47 9.51 ±0.32 9.43 ±0.30 8.17 ±0.14 - 
240 8.98 ±0.27 8.40 ±0.15 7.96 ±0.18 8.24 0.23 8.41 ±0.13 8.49 ±0.14 7.90 ±0.17 - 
2
nd
 OGTT 
(9 WOT) 
0 8.11 ±0.20 8.10 ±0.26 7.80 ±0.26 8.10 0.35 8.34 ±0.14 8.25 ±0.15 7.38 ±0.26 - 
15 12.25 ±0.52 12.59 ±0.60 11.41 ±0.22 11.71 0.36 12.58 ±0.41 12.43 ±0.26 10.23 ±0.15 ϕ 
30 13.31 ±0.54 14.01 ±1.20 11.70 ±0.27 12.68 0.35 13.42 ±0.66 13.73 ±0.43 9.04 ±0.24 λλ χχ εεεε δδδδ ωωωω ϕϕϕϕ 
60 11.94 ±1.04 12.97 ±1.13 10.43 ±0.62 11.64 0.65 13.22 ±0.84 13.02 ±0.59 9.53 ±1.84 μ εεε ωωω ϕϕϕϕ  
120 10.25 ±0.59 10.37 ±1.01 8.60 ±0.24 9.11 0.36 11.15 ±0.87 10.32 ±0.46 7.80 ±0.13 ωω ϕϕ 
240 8.95 ±0.21 8.57 ±0.23 8.66 ±0.25 8.50 0.31 8.53 ±0.19 8.73 ±0.18 7.94 ±0.11 - 
3
rd
 OGTT 
(14 WOT) 
0 7.96 ±0.29 7.81 ±0.24 8.50 ±0.25 7.45 0.18 8.43 ±0.25 8.48 ±0.22 7.61 ±0.31 - 
15 14.36 ±0.57 13.26 ±0.43 12.43 ±0.30 13.13 0.61 13.87 ±0.45 13.63 ±0.29 10.44 ±0.21 ε ωω δδδ ϕϕϕϕ 
30 16.02 ±0.92 14.51 ±0.87 12.95 ±0.72 14.58 1.03 15.64 ±0.63 15.64 ±0.46 9.41 ±0.33 μ χχ δδδδ εεεε λλλλ ωωωω ϕϕϕϕ 
60 14.94 ±1.17 14.22 ±1.10 12.34 ±1.08 13.80 0.93 15.72 ±1.12 15.46 ±0.59 7.84 ±0.23 
μμ χχχχ δδδδ εεεε λλλλ ωωωω 
ϕϕϕϕ 
120 12.44 ±1.27 10.75 ±0.86 9.48 ±0.76 10.48 0.47 12.74 ±0.91 11.87 ±0.51 7.80 ±0.13 ε δδδδ ωωωω ϕϕϕϕ 
240 8.77 ±0.32 8.79 ±0.22 8.19 ±0.20 8.54 0.26 8.49 ±0.25 8.84 v0.20 7.78 ±0.07 -  
4
th
 OGTT 
(19 WOT) 
0 8.43 ±0.40 7.96 ±0.35 8.70 ±0.41 7.45 0.43 9.54 ±0.56 8.73 ±0.27 6.84 ±0.16 - 
15 13.53 ±0.57 13.29 ±0.48 12.11 ±0.65 12.25 0.47 14.15 ±0.48 13.83 ±0.39 10.19 ±0.19 δ ωω ϕϕϕ 
30 14.49 ±0.75 14.84 ±0.87 12.60 ±1.15 13.39 0.67 15.97 ±0.50 15.30 ±0.53 11.12 ±1.73 ε δ ωωω ϕϕϕϕ 
60 14.37 ±0.99 15.25 ±1.28 12.16 ±1.13 14.31 0.82 16.25 ±0.98 15.61 ±0.63 7.81 ±0.30 μ χχ δδδδ εεεε λλλλ ωωωω ϕϕϕϕ 
120 11.89 ±1.09 11.22 ±0.87 10.20 ±1.15 11.63 0.54 12.95 ±0.97 12.86 ±0.54 9.34 ±1.85 ω ϕϕ 
240 9.26 ±0.65  8.39 ±0.34 7.84 ±0.26 8.23 0.34 8.60 ±0.63 8.29 ±0.23 7.52 ±0.21 - 
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5
th
 OGTT 
(25 WOT) 
0 7.86 ±0.29 7.51 ±0.22 7.49 ±0.24 7.29 0.22 7.95 ±0.23 7.63 ±0.17 6.42 ±0.12 - 
15 14.58 ±0.97 14.26 ±0.46 12.95 ±0.47 13.17 0.48 14.93 ±0.51 14.31 ±0.37 10.48 ±0.17 ε δδ ωω ϕϕϕ 
30 15.54 ±1.02 15.68 ±0.68 13.60 ±0.66 14.11 0.46 16.85 ±0.65 15.61 ±0.47 8.79 ±0.32 χχχ λλλ δδδδ εεεε ωωωω ϕϕϕϕ 
60 16.06 ±1.37 16.80 ±0.87 13.91 ±1.00 15.67 0.80 18.00 ±0.73 16.53 ±0.57 7.75 ±0.32 δδδδ εεεε χχχχ λλλλ ωωωω ϕϕϕϕ 
120 13.07 ±1.45 12.77 ±0.67 11.73 ±0.91 12.29 0.90 14.95 ±1.10 13.87 ±0.62 8.80 ±1.55 δδ εε ωωωω ϕϕϕϕ 
240 10.65 ±1.81 8.56 ±0.44 8.50 ±0.27 8.83 0.57 10.23 ±1.12 10.24 ±0.53 7.64 ±0.13 ϕ 
6
th
 OGTT 
(29 WOT) 
0 8.10 ±0.31 7.63 ±0.29 7.58 ±0.35 6.99 0.20 7.94 ±0.18 7.55 ±0.17 6.37 ±0.19 - 
15 15.14 ±1.31 14.61 ±0.42 12.83 ±0.53 13.58 0.62 15.22 ±1.05 14.79 ±0.35 10.02 ±0.17 εε δδδ ωωω ϕϕϕϕ 
30 16.10 ±1.34 15.64 ±0.60 13.49 ±0.73 15.40 1.09 17.45 ±1.09 16.64 ±0.43 9.02 ±0.39 χχ δδδδ εεεε λλλλ ωωωω ϕϕϕϕ 
60 16.30 ±1.69 16.23 ±0.72 14.53 ±1.15 15.76 0.85 18.51 ±1.35 17.12 ±0.47 7.85 ±0.25 δδδδ εεεε χχχχ λλλλ ωωωω ϕϕϕϕ 
120 15.14 ±1.68 14.07 ±0.97 11.95 ±0.86 13.63 0.66 16.04 ±1.27 15.28 ±0.67 7.36 ±0.18 χχ δδδδ εεεε λλλλ ωωωω ϕϕϕϕ 
240 12.27 ±2.14 9.42 ±0.71 8.15 ±0.48 8.81 0.59 10.35 ±1.07 10.65 ±0.56 7.48 ±0.22 ϕϕ δδδ 
7
th
 OGTT 
(32 WOT) 
0 8.98 ±0.56 7.66 ±0.33 7.76 ±0.24 7.84 0.28 9.11 ±0.65 7.96 ±0.16 6.89 ±0.13 - 
15 16.50 ±1.35 15.15 ±0.62 13.66 ±0.42 13.79 0.47 16.04 ±1.36 15.22 ±0.41 10.31 ±0.19 εε ωωω δδδ ϕϕϕϕ 
30 17.98 ±1.52 16.70 ±0.77 14.59 ±0.75 15.98 0.38 17.74 ±1.62 16.79 ±0.43 8.99 ±0.50 χχ δδδδ ωωωω λλλλ εεεε ϕϕϕϕ 
60 18.29 ±1.74 17.84 ±0.93 15.34 ±1.19 17.59 0.76 17.29 ±1.12 17.84 ±0.60 7.76 ±0.32 δδδδ χχχχ ωωωω λλλλ εεεε ϕϕϕϕ 
120 15.93 ±2.17 15.47 ±0.95 12.54 ±1.25 16.25 0.68 15.76 ±1.81 16.02 ±0.70 7.61 ±0.21 χχ δδδδ ωωωω λλλλ εεεε ϕϕϕϕ 
240 12.55 ±2.45 9.68 ±1.05 8.43 ±0.40 9.71 0.93 10.60 ±1.59 11.61 ±0.71 7.64 ±0.16 ϕϕ δδδ 
Table 8: Means and standard error of means of the glucose levels (mmol/l) of all groups at the different timepoints (0, 15, 30, 60, 120, 240 minutes) in all OGTTs. See 
legend of symbols for significant differences. WOT = weeks of treatment. 
 
Weeks of 
treatment 
Tg 0.3mg/kg  
(mmol/l/min) 
Tg 1mg/kg  
(mmol/l/min) 
Tg 3mg/kg  
(mmol/l/min) 
Tg 10mg/kg  
(mmol/l/min) 
Tg LALA-PG  
(mmol/l/min) 
Tg PBS 
(mmol/l/min) 
WT PBS 
(mmol/l/min) 
Significances 
4 2431 ±97 2291 ±77 2136 ±66 2234 ±63 2405 ±52 2409 ±62 2051 ±40 δ ω ϕϕ 
9 2541 ±106 2596 ±171 2256 ±55 2375 ±66 2664 ±127 2596 ±78 2019 ±85 δ ε ωω ϕϕϕ 
14 2954 ±186 2719 ±143 2441 ±140 2657 ±92 2987 ±147 2914 ±85 1947 ±27 λλ εεε δδδδ ωωωω ϕϕϕϕ 
19 2865 ±183 2793 ±147 2466 ±176 2725 ±83 3056 ±157 2975 ±93 2098 ±201 δ ε ωωω ϕϕϕϕ 
25 3165 ±324 3042 ±99 2748 ±133 2910 ±136 3432 ±200 3229 ±116 2002 ±148 εε δδδ ωωωω ϕϕϕϕ 
29 3483 ±389 3190 ±150 2771 ±145 3067 ±120 3578 ±262 3438 ±109 1865 ±38 δδδδ ωωωω εεεε ϕϕϕϕ 
32 3729 ±456 3436 ±187 2916 ±189 3462 ±124 3541 ±349 3607 ±136 1902 ±44 εεε δδδδ ωωωω ϕϕϕϕ 
Table 9: Means and standard error of means of the glucose AUC (mmol/l/min) of different treatment groups in all OGTTs. See legend of symbols for significant 
differences. 
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Figure 16: Comparison of the glucose AUC (mmol/l/min) of groups in the baseline OGTT and 7th OGTT. See legend of 
symbols for significant differences. 
Insulin response 
The insulin response was measured during the baseline OGTT and the 1st, 2nd, 5th and 7th OGTT. 
In the baseline OGTT, the Tg rats already had significantly lower insulin levels in the 30-, 120- 
and 240-minute timepoints. Over all OGTTs, various Tg groups showed a highly significant 
decrease in insulin compared to WT in mostly the 15-, 30-, 60- and 240-minute time points. In 
the first OGTT, all groups except for the 1 and 10mg/kg had significantly lower insulin levels in 
the 30- and 120-minute timepoints. Compared to this, all the Tg groups differed significantly 
from the WT PBS only in the 15-minute timepoint in the 2nd OGTT. In the 5th OGTT however, 
all Tg groups had significantly lower insulin levels than the WT PBS in the 15-, 30-, 60- and 240-
minute timepoint. Less of a difference was observed in the 7th OGTT, where all Tg groups had 
significantly lower insulin levels compared to the WT PBS in the 15- and 30-minute time points; 
and all Tg groups except for the 1mg/kg Tg group in the 240-minute timepoint. Throughout all 
the OGTTs, there were also individual points in time when only the LALA-PG or Tg PBS groups 
had significantly decreased insulin level compared to WT PBS. No significant difference in 
insulin response was seen at any the time point between the transgenic treatment groups. (Table 
10). 
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(min) Tg 0.3mg/kg (µg/l) Tg 1mg/kg (µg/l) Tg 3mg/kg (µg/l) Tg 10mg/kg (µg/l) Tg LALA-PG (µg/l)  Tg PBS (µg/l) WT PBS Significances 
Baseline OGTT 
(-1 WOT) 
0 0.13 ±0.00 0.16 ±0.01 0.12 ±0.01 0.15 ±0.01 0.14 ±0.01 0.15 ±0.01 0.16 ±0.01 - 
15 0.13 ±0.02 0.18 ±0.03 0.09 ±0.01 0.14 ±0.02 0.12 ±0.01 0.13 ±0.01 0.19 ±0.03 - 
30 0.10 ±0.01 0.16± ±0.02 0.10 ±0.02 0.14 ±0.01 0.13 ±0.02 0.13 ±0.01 0.24 ±0.06 λ ωω δδδ χχχ ϕϕϕϕ 
60 0.16 ±0.02 0.18 ±0.04 0.10 ±0.01 0.13 ±0.01 0.12 ±0.01 0.17 ±0.02 0.14 ±0.02 - 
120 0.13 ±0.01 0.21 ±0.03 0.13 ±0.01 0.18 ±0.01 0.16 ±0.02 0.17 ±0.01 0.25 ±0.06 ω ϕ δδ χχ 
240 0.13 ±0.01 0.17 ±0.01 0.11 ±0.01 0.15 ±0.01 0.11 ±0.01 0.16 ±0.01 0.22 ±0.03 χ ωω 
1
st 
OGTT 
(4 WOT) 
0 0.08 ±0.00 0.13 ±0.01 0.08 ±0.01 0.11 ±0.02 0.10 ±0.01 0.10 ±0.01 0.22 ±0.04 - 
15 0.13 ±0.02 0.16 ±0.02 0.14 ±0.02 0.21 ±0.04 0.17 ±0.02 0.15 ±0.02 0.31 ±0.04 - 
30 0.02 ±0.01 0.08 ±0.01 0.04 ±0.01 0.08 ±0.02 0.04 ±0.01 0.05 ±0.01 0.22 ±0.03 λ ωω δδδ χχχ ϕϕϕϕ 
60 0.10 ±0.02 0.13 ±0.03 0.07 ±0.02 0.22 ±0.06 0.10 ±0.02 0.11 ±0.01 0.23 ±0.03 - 
120 0.12 ±0.01 0.20 ±0.03 0.14 ±0.02 0.24 ±0.03 0.15 ±0.04 0.15 ±0.01 0.22 ±0.03 ω ϕ δδ χχ 
240 0.10 ±0.01 0.11 ±0.01 0.09 ±0.01 0.20 ±0.03 0.13 ±0.02 0.09 ±0.01 0.15 ±0.02 χ ωω 
2
nd
 OGTT 
(9 WOT) 
0 0.25 ±0.01 0.29 ±0.02 0.25 ±0.02 0.30 ±0.01 0.26 ±0.01 0.26 ±0.01 0.43 ±0.06 ϕ 
15 0.30 ±0.04 0.36 ±0.05 0.38 ±0.12 0.48 ±0.08 0.31 ±0.02 0.32 ±0.02 0.71 ±0.11 λ δδδδ χχχχ ωωωω εεεε ϕϕϕϕ 
30 0.24 ±0.03 0.35 ±0.05 0.27 ±0.07 0.32 ±0.05 0.22 ±0.02 0.28 ±0.02 0.41 ±0.03 λ 
60 0.47 ±0.04 0.57 ±0.07 0.47 ±0.03 0.60 ±0.09 0.50 ±0.03 0.50 ±0.03 0.48 ±0.08 - 
120 0.38 ±0.05 0.46 ±0.04 0.31 ±0.04 0.47 ±0.07 0.34 ±0.03 0.40 ±0.03 0.41 ±0.04 - 
240 0.34 ±0.03 0.40 ±0.03 0.28 ±0.04 0.38 ±0.03 0.31 ±0.03 0.32 ±0.01 0.53 ±0.06 χ ω ϕϕ 
5
th
 OGTT 
(25 WOT) 
0 0.22 ±0.02 0.29 ±0.02 0.20 ±0.02 0.24 ±0.02 0.24 ±0.02 0.23 ±0.01 0.38 ±0.04 - 
15 0.36 ±0.04 0.42 ±0.03 0.35 ±0.02 0.35 ±0.04 0.36 ±0.05 0.43 ±0.05 1.53 ±0.25 δδδδ χχχχ ωωωω λλλλ εεεε ϕϕϕϕ 
30 0.33 ±0.04 0.38 ±0.03 0.28 ±0.02 0.30 ±0.01 0.33 ±0.04 0.33 ±0.02 0.87 ±0.12 δδδδ χχχχ ωωωω λλλλ εεεε ϕϕϕϕ 
60 0.42 ±0.04 0.64 ±0.09 0.38 ±0.03 0.47 ±0.08 0.43 ±0.04 0.44 ±0.02 0.96 ±0.12 ε λλλ δδδδ χχχχ ωωωω ϕϕϕϕ 
120 0.42 ±0.04 0.59 ±0.09 0.42 ±0.06 0.53 ±0.08 0.44 ±0.06 0.46 ±0.02 0.70 ±0.08 ϕ 
240 0.53 ±0.09 0.58 ±0.06 0.45 ±0.05 0.47 ±0.06 0.47 ±0.05 0.52 ±0.03 0.97 ±0.08 εε λλλ δδδ χχχχ ωωωω ϕϕϕϕ 
7
th
 OGTT 
(32 WOT) 
0 0.42 ±0.14 0.38 ±0.04 0.28 ±0.01 0.30 ±0.02 0.29 ±0.03 0.28 ±0.01 0.45 ±0.04 - 
15 0.62 ±0.18 0.58 ±0.08 0.45 ±0.06 0.45 ±0.05 0.37 ±0.03 0.42 ±0.03 1.76 ±0.23 δδδδ χχχχ ωωωω λλλλ εεεε ϕϕϕϕ 
30 0.39 ±0.10 0.33 ±0.04 0.28 ±0.05 0.30 ±0.04 0.21 ±0.02 0.28 ±0.02 0.86 ±0.16 δδ χχχ λλλ εεε ωωωω ϕϕϕϕ 
60 0.59 ±0.18 0.57 ±0.07 0.52 ±0.0 0.52 ±0.06 0.39 ±0.04 0.42 ±0.02 0.91 ±0.12 ωω ϕϕϕϕ 
120 0.64 ±0.17 0.70 ±0.05 0.61 ±0.04 0.68 ±0.09 0.56 ±0.10 0.55 ±0.04 0.91 ±0.14 ϕϕ 
240 0.65 ±0.16 0.75 ±0.13 0.55 ±0.07 0.60 ±0.09 0.58 ±0.08 0.52 ±0.03 1.07 ±0.14 δ λ χχ ωω ϕϕϕϕ 
Table 10: Means and standard error of means of insulin levels (μg/l) of groups at the different points in time (0, 15, 30, 60, 120, 240 minutes) in all OGTTs. See legend of 
symbols for significant differences. WOT = weeks of treatment. 
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At the baseline OGTT, the insulin AUC already differed significantly between the WT and Tg 
rats. In the 1st OGTT, all Tg groups except for the 10 and 1mg/kg groups had a smaller insulin 
AUC compared to the WT PBS group. In the 5th and 7th OGTT, a decrease in the insulin AUC of 
all Tg groups was observed compared to the WT PBS group. In the 1st OGTT, the 10mg/kg group 
had a significantly larger AUC than the 0.3 and 3mg/kg group as well as the LALA-PG and Tg 
PBS groups. Apart from that, no significant difference in insulin response was seen in any time  
points or in the AUC between the Tg groups in any of the OGTTs (Table 11, Figure 17). 
 
 
WOT 
Tg 0.3mg/kg 
(µg/l/min) 
Tg 1mg/kg 
(µg/l/min) 
Tg 3mg/kg 
(µg/l/min) 
Tg 10mg/kg 
(µg/l/min) 
Tg LALA-PG 
(µg/l/min) 
Tg PBS 
(µg/l/min) 
WT PBS 
(µg/l/min) 
Significances 
4 24.45 ±1.72 35.57 ±4.67 24.57 ±3.96 49.57 ±7.03 30.11 ±5.40 27.92 ±1.33 50.82 ±5.56 
ωω δδδ χχχ πππ 
ϕϕϕϕ 
9 88.06 ±8.62 106.10 ±8.83 80.08 ±8.97 108.70 ±13.18 82.90 ±5.88 90.64 ±4.24 113.50 ±8.99 
- 
  
25 102.5 ±10.56 133.80 ±11.83 95.19 ±8.18 110.80 ±11.81 101.40 ±10.33 107.40 ±4.25 210.20 ±15.76 
δδδδ χχχχ ωωωω 
λλλλ εεεε ϕϕϕϕ 
32 144.4 ±38.50 152.70 ±15.36 125.9 ±9.15 136.10 ±13.86 115.30 ±15.87 114.10 ±5.37 235.30 ±27.89 
δ λ ε χχ ωωω 
ϕϕϕϕ 
Table 11: Means and standard error of means of AUC (area under curve) of all groups in the 1st, 2nd, 5th and 7th OGTT. 
See legend of symbols for significant differences. 
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Figure 17: Comparison of the insulin AUC (area under curve) in μg/l/min of all groups in the 1st, 2nd, 5th and 7th OGTT. 
See legend of symbols for significant differences. 
Fasting plasma IAPP levels 
Fasting plasma IAPP levels were measured at the baseline OGTT as well as the 2nd, 4th, 5th and 
7th OGTT. The levels of all groups stayed consistent except for the Tg LALA-PG and 10mg/kg 
groups, which had increased plasma IAPP levels in some of the OGTTs (Figure 18). When 
comparing the IAPP levels of the WT to the Tg rats, the WT PBS group had significantly 
decreased IAPP levels compared to the 10mg/kg group in the 2nd and 4th OGTT, as well as 
compared to the LALA-PG group in the 7th OGTT. Within the Tg rats, the 10mg/kg had 
significantly higher IAPP levels than the Tg PBS group in the 2nd OGTT. Also, the 10mg/kg 
group had significantly higher IAPP levels than the Tg PBS, 0.3, 1 and 3mg/kg groups in the 4th 
OGTT. In the 7th OGTT, the IAPP levels of the Tg LALA-PG group was significantly higher 
than that of the Tg PBS, 1 and 3mg/kg groups (Figure 18, Table 12). 
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Figure 18: Course of plasma IAPP (pmol/l) levels of all groups over 32 weeks. See legend of symbols for significant 
differences. 
 
OGTT 
Tg 0.3mg/kg 
(pmol/l) 
Tg 1mg/kg  
(pmol/l) 
Tg 3mg/kg  
(pmol/l) 
Tg 10mg/kg 
(pmol/l) 
Tg LALA-PG 
(pmol/l) 
Tg PBS  
(pmol/l) 
WT  
(pmol/l) 
Significances 
Baseline 28.3 ±9.5 98.0 ±16.1 57.5 ±19.8 49.6 ±18.0 78.6 ±23.0 69.4 ±12.0 32.1 ±7.5 - 
2
nd
 74.4 ±25.5 99.3 ±14.9 97.7 ±24.8 627.7 ±321.3 220.8 ±110.7 90.7 ±11.0 65.3 ±10.0 λ π 
4
th
 137.5 ±28.7 152.7 ±22.1 132.8 ±22.0 776.4 ±447.0 294.6 ±114.7 149.4 ±16.0 172.2 ±23.2 λ π π 
5
th
 151.8 ±69.6 77.5 ±4.1 96.7 ±15.0 442.3 ±210.1 444.0 ±341.3 86.5 ±8.5 56.8 ±12.3 - 
7
th
 215.2 ±121.3 111.6 ±19.6 117.4 ±26.1 210.0 ±51.6 712.8 ±611.5 88.9 ±8.4 84.8 ±11.6 ωω*** 
Table 12: Means and standard error of means of the baseline IAPP levels (pmol/l) of all groups before the baseline, 2nd, 4th, 
5th and 7th OGTT. See legend of symbols for significant differences. 
5.4. Pharmacokinetics and –dynamics (PK/PD) 
Due to a lack of progression of the diabetic phenotype in the expected time frame, this part of the 
study was postponed. This is discussed in further details in the general Discussion.  
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5.5. Target engagement  
After a long trial regarding target engagement in fixed rat pancreas, it was discovered that this 
could only be achieved in unfixed frozen pancreas. This is most likely because the hNI-
203.26C11-bound oligomeric hIAPP species are sensitive to fixation and do not preserve their 
native conformation recognized by hNI-203.26C11. 
Based on this finding, the following protocol was established: 3 days after a single injection of 
hNI-203.26C11 antibody (30 mg/kg) or vehicle in HIP rats, the rats were sacrificed and the 
pancreas was harvested. The unfixed, frozen pancreas sections were incubated with a 
fluorescently-labeled anti-human antibody. This was combined with insulin counterstaining. 
Together, this resulted in the visualization of diffuse extracellular IAPP aggregates around 
insulin-producing β-cells. As a control, these were compared to the pancreata of HIP rats after a 
single injection of vehicle following the same protocol (Figure 19).  
 
 
Figure 19: Pancreas immunostaining for insulin (1° guinea pig anti-insulin AB and 2° TRITC-labeled antibody) and hNI-
203.26C11 with a fluorescent 2° anti-human antibody (Neurimmune AG) after a single injection of hNI-203.26C11 or 
vehicle in HIP rats. Serving as a control, the fluorescently labeled hNI-203.26C11 occurs specifically in rats treated with 
hNI-203.26C11, but not in those injected with PBS. The fluorescently labeled insulin occurs to a similar extent in both 
rats. When merging these two images, the hNI-203.26C11 antibody areas overlap with insulin-rich areas in the rats 
injected with hNI-203.26C11. This indicates that these diffuse extracellular IAPP oligomers are surrounding insulin-
producing β-cells. 
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6. Discussion 
T2D is characterized by insulin resistance, defective insulin secretion, hyperglycemia, loss of β-
cell mass and function as well as micro- and macrovascular complications (Stumvoll et al. 2005; 
Despa et al. 2012). This condition is initially caused by insulin resistance and leads to an 
activation of several compensation mechanisms, namely an initial increase in β-cell mass and 
insulin secretion. This increased insulin secretion is accompanied by increased IAPP secretion, as 
both are stored and co-secreted in vesicles of β-cells. In turn, increased IAPP secretion facilitates 
the aggregation of pathogenic IAPP. In this process cytotoxic IAPP oligomers are formed, which 
induce oxidative stress, islet inflammation and β-cell apoptosis (Abedini et al. 2016). So far, there 
are no therapies that aim to prevent the process of IAPP aggregation or that target these cytotoxic 
oligomers specifically. Therefore, the novel approach of antibody therapy tested in this study has 
great potential. Based on this, the lead antibody NI-203.26C11 was selected for in vivo testing 
after the initial identification and production of antibody candidates with high selectivity and 
affinity for toxic hIAPP oligomers, but not monomeric IAPP or large extracellular IAPP deposits. 
Animal model 
For the animal model, rats transgenic for hIAPP expression (HIP rats) were chosen due to the 
pathophysiologic process of hIAPP aggregation shared with humans suffering from T2D. As in 
diabetic humans, middle-age diabetes develops spontaneously in HIP rats and progresses with 
age. The islet pathology corresponds to that in humans and ultimately results in hyperglycemia, 
insulin resistance and decreased β-cell mass (Matveyenko and Butler 2006). Further, this model 
does not require severe obesity for the development of diabetes, as HIP rats develop diabetes 
spontaneously and independent from obesity. Based on this, the HIP model mimics many facets 
of the metabolic syndrome, but in particular IAPP aggregation, which is not present in other 
frequently used rodent models.  
In mouse models, mice transgenic for hIAPP expression were crossed with obese mouse models, 
for example ob/ob mice (Höppener et al. 1999), (a(vy)/a) mice (Soeller et al. 1998; Geisler et al. 
2002; Butler et al. 2003). This resulted in heterozygous mouse models that reflect both the 
pathogenic role of hIAPP expression as well as the pathogenic aspect of lipotoxicity. Up to this 
time point, no such rat model had been developed or is available for purchase. HIP rats were also 
used as animal model in previous studies conducted by our group in collaboration with 
Neurimmune AG.  
Observations of previous studies 
After a 30-week treatment with chimeric rNI-203.26C11 (3mg/kg) in an initial study, first 
beneficial effects were observed in HIP rats, resulting in improved glucose tolerance, decreased 
fasting glucose, increased plasma insulin levels and normalized body weight gain (M. Osto 2014, 
2015). These changes indicate an overall preservation of β-cell function. In a further study, the 
efficacy of three different dosages (1, 3 and 10mg/kg) was examined over a period of 40 weeks 
(Hugentobler 2017). In that study, the protective effect on β-cells observed beforehand was 
reconfirmed, as all three dosages slowed the progression of diabetes, yet without a clear dose-
response relationship. Additionally, WT rats treated with the same dosages showed no unspecific 
side effects.  
Aims of the present study 
In the present study, the three main aims were the following: to investigate the long- and short-
term efficacy of four different dosages of rNI-203.26C11, to examine the mechanisms of action 
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more closely and to develop a method of visualization and quantification of rNI-203.26C11 
mediated hIAPP clearance. 
6.1. Beneficial effects of long-term treatment 
The first aim of this study was to investigate the long-term effect of four different dosages of rNI-
203.26C11 (0.3, 1, 3, 10mg/kg) on BW gain, β-cell function and plasma IAPP levels in glucose 
intolerant HIP rats. After 32 weeks of treatment, a decrease in BW was observed in the PBS, 
0.3mg/kg and LALA-PG (an inert version of the antibody rNI-203.26C11) treated Tg groups 
compared to the WT PBS. This was paralleled by an increase in fasting glucose levels and 
glucose AUC. However, these observations were not made concerning the 1, 3 and 10mg/kg rNI-
203.26C11 treated groups. This indicates an early protective effect on β-cell viability and a 
slowing of the progression of T2D in dosages ranging between 1 and 10mg/kg, although not in a 
strictly dose dependent manner.  
Effect on BW 
Up to 45 weeks of age, a general BW gain was observed in the antibody-treated Tg groups 
ranging from a dose of 1 to 10mg/kg as well as the WT PBS. No plateau was reached up to this 
point. However, a significant decrease in BW gain occurred in the 0.3mg/kg, LALA-PG and Tg 
PBS treated groups compared to the WT PBS group from 42 weeks of age onwards. This 
decrease in both PBS and 0.3mg/kg treated Tg groups progressed to be highly significant at 43, 
respectively 44, weeks of age. BW loss is thought to reflect at least in part energy loss by 
glucosuria due to insulin deficiency. Based on that, this observation indicates that a long-term 
treatment with the antibody NI-203.26C11 delays the development of a diabetic phenotype, but 
was unable to prevent it, at least at this low antibody dose. This protective effect was also 
observed in our previous studies, where the BW of the antibody treated groups ranging from a 
dosage of 1 to 10mg/kg remained stable compared to the Tg PBS group, which lost weight from 
25 weeks of treatment (37 weeks of age) onwards (Hugentobler 2017). Nonetheless, in this study 
the 10mg/kg group also began to show a significant decrease in BW gain compared to the WT 
PBS group at 45 weeks of age. This occurrence might be the first indication of the development 
of a diabetic phenotype in all Tg rats regardless of their treatment.  
Effect on FI 
In the development of the HIP rat model, a certain variability concerning FI levels had been 
observed in both Tg and WT rats (Butler et al. 2004). This variability was also seen in our 
groups, as no consistent changes were observed between our Tg groups. Despite the overlap in 
values due to the inter-individual variability, the Tg rats developed insulin deficiency at 10 
months of age compared to WT rats (Butler et al. 2004; Aitken et al. 2017; Matveyenko and 
Butler 2006). In this study, the FI levels of the Tg PBS rats showed a highly significant decrease 
from the 1st until the last OGTT compared to the WT rats, from an age of 16 weeks onwards. A 
similar situation was observed in our previous study, where a significantly decreased FI occurred 
when comparing the Tg PBS to the WT PBS in the 2nd OGTT and again from the 6th OGTT until 
sacrifice. Just as in our study, no significant differences were observed between the Tg groups 
(Hugentobler 2017). However, significantly lower FI values were observed in the Tg 0.3mg/kg, 
3mg/kg and PBS group compared to the WT PBS group from the 1st OGTT and in the LALA-PG 
group from the 2nd OGTT on in this study. Out of all the groups, it seems that FI of the 1mg/kg 
treatment group was overall higher than that of the other Tg groups, therefore not resulting in a 
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significant difference compared to the WT PBS. This observation may correspond to a delayed 
onset of impaired β-cell function.  
Effect on insulin AUC and response 
The key physiological function of insulin is to respond to an increase in blood sugar levels and 
consequently cause a decrease in circulating glucose levels. Based on this notion, the insulin 
response is thought to reflect β-cell function more accurately than the glucose response. This 
notion is confirmed by the observation that a defective insulin response precedes hyperglycemia 
in both HIP rats as well as humans with T2D (Matveyenko and Butler 2006; Boden et al. 1968; 
van Haeften et al. 1998). In this study, all Tg groups had a significantly decreased insulin AUC in 
the 1st OGTT (except for the 10mg/kg Tg group) as well as in the 5th and 7th OGTT compared to 
the WT PBS. This increased insulin AUC of the 10mg/kg group compared to the Tg PBS was 
also observed in the 2nd OGTT at 20 weeks of age in a previous study (Hugentobler 2017). 
Interestingly, no significant differences occurred between the groups in the 2nd OGTT in the 
current study. In the 1st OGTT, the insulin AUC of the 10mg/kg treatment group was increased in 
comparison to all Tg groups except for 1mg/kg Tg group. No significant difference between Tg 
groups occurred in the following OGTTs. These significant differences between the Tg groups 
and the WT PBS were also reflected in the insulin levels at the different points in time of the 
OGTT, while no significant differences were observed between the Tg groups.  
Overall, this suggests that all the Tg groups developed an impaired insulin response to some 
degree between the age of 22 and 27 weeks of age independent of treatment or dosage. Therefore, 
the long-term treatment with rNI-203.26C11 was not able to lead to a significant reduction in the 
progression of glucose intolerance in the current study. 
Effect on FG 
In previous papers, a progressive increase in FG was observed in Tg HIP rats. This increase is 
thought to reflect progressive β-cell loss. Overall, we observed a highly significant increase in FG 
levels of the 0.3mg/kg, LALA-PG and Tg PBS group compared to the WT PBS from the 4th 
OGTT (32 weeks of age, 19 weeks of treatment, respectively). Compared to this, no consistently 
higher FG levels were observed in the Tg 1mg/kg, 3mg/kg and 10mg/kg treatment groups 
compared to the WT PBS. This also indicates that long-term treatment with NI-203.26C11 has a 
protective effect of on β-cell function. In the previous study concerning the efficacy of three 
dosages of rNI-203.26C11 in long-term therapy (Hugentobler 2017), significantly lower FG 
levels were observed in the Tg 3mg/kg group (5th and 6th OGTT), in the 1mg/kg group (8th to 10th 
OGTT) as well as in the 10mg/kg group (10th OGTT) compared to the Tg PBS group. Concurrent 
with our study, no significant differences were observed between the different dosage groups. 
The β-cell content of the rats in our experiment has yet to be histologically determined. 
Effect on glucose AUC and response 
The cytotoxic effect of hIAPP oligomers on β-cells leads to a decrease in β-cell mass and 
function. This leads to impaired insulin secretion, which in turn results in glucose intolerance 
(Haataja et al. 2008; Jurgens et al. 2011; Butler et al. 2004). When examining the glucose 
tolerance in the OGTTs, less of an impaired glucose response was observed in the 3 and 10mg/kg 
treatment groups compared to the other Tg groups. Compared to the WT PBS, the 0.3mg/kg, 
LALA-PG and Tg PBS groups had significantly increased glucose AUCs in all OGTTs, while the 
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1mg/kg group did so from the 2nd OGTT onwards. In contrast, the glucose AUC of the 3mg/kg 
group was never increased significantly, and that of the 10mg/kg group was increased only in the 
3rd OGTT compared to the WT PBS. In our previous study (Hugentobler 2017), an overall lower 
glucose AUC was observed in the 1 and 10mg/kg Tg treatment groups from the 2nd until the 8th 
OGTT (20 to 46 weeks of age). In the present study, however, no consistent significant 
differences were observed within the Tg treatment groups. From the 1st to the 4th OGTT, the 
glucose levels of the 3mg/kg group were significantly lower than those of the Tg PBS group in 
the 30- or 60-minute time points, or both. Also, except for the 7th OGTT, a significant decrease in 
glucose levels was observed in the 3mg/kg group compared to the LALA-PG 10mg/kg group in 
at the 60- and/or 120-minute time points in all OGTTs. In the last OGTT, no significant 
difference in glucose tolerance or in glucose AUC was seen at any time point between the Tg 
groups. Compared to the WT rats, all Tg groups showed significantly higher glucose levels in the 
15-minute point, except for the 3 and 10mg/kg groups. All Tg groups had significantly higher 
glucose levels in the 30-, 60- and 120-minute time points. At the 240-minute point, only the 
0.3mg/kg and Tg PBS groups still had elevated glucose levels compared to the WT PBS group. 
On one hand, these observations may reflect an impaired glucose response independent of 
treatment during the experiment, while it is less severe in the 3 and 10mg/kg treatment groups. 
On the other hand, these observations indicate an enhanced glucose response in both the 3 and 
10mg/kg groups compared to the other Tg groups.  
Effect of treatment with rNI-203.26C11 on plasma IAPP 
Plasma IAPP levels were measured using a commercial ELISA assay detecting both monomeric 
human and rat IAPP. As the antibody NI-203.26C11 binds to aggregated hIAPP oligomers 
specifically, it is unlikely that NI-203.26C11-bound IAPP or aggregated IAPP was detected in 
the ELISA assay. In previous studies (Matveyenko and Butler 2006), no difference in fasting 
plasma IAPP level was observed between the Tg PBS and WT PBS groups from 2 to 10 months 
of age. When comparing fasting plasma IAPP levels, in our study both those of the 10mg/kg 
treated rNI-203.26C11 and the LALA-PG rNI-203.26C11 group were significantly higher than 
those of the Tg and WT PBS groups, but at different points in time. In the 10mg/kg rNI-
203.26C11 treated Tg group, a plasma IAPP peak was observed between 22 and 32 weeks of age 
(in the 2nd and 4th OGTT). In a previous study, a similar phenomenon was observed (M. Osto 
2014); after 18 weeks of treatment (at an age of 30 weeks), a peak in plasma hIAPP levels 
occurred in the 3mg/kg rNI-203.26C11 treated Tg rats but not in the Tg PBS control group. In 
that study those two groups were not compared to WT rats, nor to other dosages. In the 7th OGTT 
of our study (32 weeks of treatment, 45 weeks of age), the LALA-PG rNI-203.26C11 group 
(10mg/kg) had significantly increased plasma IAPP levels compared to both Tg and WT PBS 
treated groups. This might reflect either an increased formation and production of free IAPP or an 
increased IAPP elimination from the pancreas into the blood. Both would be a further indication 
of the beneficial effect of antibody treatment with rNI-203.26C11.  
Effect of rNI-203.26C11 dose on plasma IAPP levels 
In the first instance, it appears that a correlation exists between the increased plasma IAPP level 
and the administration of a higher dosage of antibody, as an this was only observed in both the 
10mg/kg rNI-203.26C11 and LALA-PG rNI-203.26C11 treated groups. The underlying cause of 
this observation is most likely linked to further mechanisms of action other than macrophage 
activation. On one hand, this might be the indirect result of inhibited IAPP aggregation through 
catalytic dissolution(Morgan 2011)(Morgan 2011) (Solomon et al. 1996; Solomon et al. 1997; 
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Schenk et al. 1999), resulting in a greater amount of free IAPP monomers. On the other hand, this 
might also be due to an increased clearance of monomeric soluble hIAPP or disassembly of 
hIAPP aggregates which may be detected by the assay, combined with increased IAPP secretion 
resulting from improved β-cell function. Overall, this observation supports the theory that more 
than one mechanism of action is involved in the inhibition of aggregation and hIAPP clearance. 
Despite the similar binding profiles of the inert LALA-PG rNI-203.26C11 compared to rNI-
203.26C11, a timewise difference in the occurrence of the elevated plasma hIAPP values was 
observed. This might reflect the importance of other mechanisms of action, leading to a delay in 
hIAPP clearance in the rats treated with the inert LALA-PG NI-203.26C11 compared to the 
10mg/kg NI-203.26C11 treated rats. Based on this, this observation is most likely linked to 
efficacy. In the development of antibody therapy in AD, plasma Aβ levels were also examined 
over a time span of 500 hours following a single dose application of aducanumab or 3D6 
(Sevigny et al. 2016). A single dose of aducanumab, which does not bind to Aβ monomers, did 
not result in increased Aβ concentrations in the plasma or brain, even after repeated dosing. In 
comparison, a single dose administration of 3D6, a murine bapineuzumab precursor antibody 
with the ability to bind to Aβ monomers, resulted in a transient plasma Aβ spike 100h post-
dosing. Therefore, it was assumed that there is a correlation between the ability to bind soluble 
Aβ and the observed plasma Aβ peak. One possible explanation to this observation is the 
peripheral sink mechanism, which postulates an Aβ clearance by the binding of free circulating 
antibodies to free Aβ (DeMattos et al. 2001). As our antibody NI-203.26C11 mostly binds 
specifically to pathogenic hIAPP oligomers and not to physiological monomers, a similar 
outcome as in aducanumab was expected, namely no increase in plasma IAPP levels. As an 
increase did indeed occur between 22 and 32 weeks of treatment, there may possibly be another, 
yet unknown long-term mechanism apart from the peripheral sink mechanism, which was not 
observed in the development of aducanumab. 
6.2. Variability in the HIP rat model 
Over the course of our previous studies, a variable diabetic phenotype of the transgenic HIP rats 
was observed. A delay in the progression of the diabetic phenotype was already observed in some 
of our previous studies. In our present study, there was a slow progression of the diabetic 
phenotype up to 45 weeks of age (approx. 10 months). These rats were obtained from Charles 
River, where they had been stored as cryopreserved embryos and then revitalized. As in many 
other lines, these animals descend from a very narrow breeding base. In HIP rats of the line 9, the 
midlife onset of the diabetic phenotype was described to occur from an age of 5 to 10 months of 
age, which coincides with a β-cell loss of 70-80%. This diabetic phenotype is characterized by 
progressive polyuria and polydipsia (PU/PD), a decrease in body weight of up to 20% compared 
to the WT from 5 months of age on, as well as impaired fasting glucose (Butler et al. 2004; 
Matveyenko and Butler 2006). 
Variability concerning PU/PD 
In our previous study, PU/PD and weight loss were observed in Tg PBS rats from 37 weeks of 
age. So far, this does not match our observations in the current study, where no generalized 
PU/PD or BW loss was seen up to an age of 45 weeks.  
Variability concerning BW loss 
In three individual rats of different treatment groups (3 and 10mg/kg, Tg PBS), a diabetic 
phenotype paired with severe BW loss was indeed observed at about 43 weeks of age. However, 
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on average, an overall BW gain was observed in all groups up to the age of 45 weeks, and no 
plateau was reached up to this point. The mean BW of the Tg PBS rats was significantly 
decreased compared to that of the WT PBS rats from 14 weeks of age. At 45 weeks (10 months) 
of age, our Tg PBS rats weighed 13.5% less that the WT rats. In comparison, transgenic HIP rats 
weighed approximately 20% less than WT rats from 5 months on (Butler et al. 2004). In a 
previous study (Hugentobler 2017), a weekly decrease in BW of approximately 0.5% was 
observed in the Tg PBS rats from 37 weeks of age, which progressed to a total loss of around 8% 
by the end of the study at 53 weeks of age. The smaller difference in mean BW observed in our 
Tg PBS rats compared to the WT PBS rats as well as the absence of weight loss of the Tg PBS 
groups might be indicative of a delay in the development of the diabetic phenotype.  
Variability concerning impaired FG 
While developing the HIP rat model, an impaired FG was observed from 5 months of age 
(7.1mmol/l), which progressed to 10.3mmol/l at 10 months of age (Butler et al. 2004; 
Matveyenko and Butler 2006). Subsequently, a further increase in FG was observed from 
10mmol/l (10 months of age) up to about 15mmol/l (18 months of age) (Butler et al. 2004). In 
one of our previous dose response studies (Hugentobler 2017), three dosage groups (1, 3, 
10mg/kg) were compared to Tg and WT PBS groups over the course of 41 weeks of treatment. In 
the Tg PBS group, mean FG levels of 7.8mmol/l were measured at approximately 5 months of 
age (20 weeks of age) and 9.4mmol/l at approximately 10 months of age (30 weeks of age). 
While a significant difference in FG occurred early on when comparing the Tg to the WT PBS 
groups (from 12 weeks of age), differences within the Tg groups were observed from 26 weeks of 
age onwards. In the present study in comparison, no significant difference in FG was observed 
when comparing the Tg PBS group to the WT PBS group until 32 weeks of age (4th OGTT). A 
significant increase in the FG was observed in the 0.3mg/kg, LALA-PG treatment groups 
compared to the WT PBS from the 4th to the 7th OGTT (32 until 45 weeks of age), but no 
consistent significant changes were observed between the treatment groups. While the mean FG 
value of the Tg PBS rats was 8.3mmol/l at 5 months of age, it decreased to a mean FG of 
8.0mmol/l at 10 months of age. Further, the Tg rats had an impaired glucose response and 
significantly higher glucose AUC values compared to the WT rats in the baseline OGTT, and yet 
still no significant differences in AUC values could be observed between the Tg groups 
throughout all OGTTs. These observations may also reflect a delay in progression caused by the 
different treatments of the diabetic phenotype, as the difference in the values of the treatment 
groups is not pronounced enough to result in significance.  
Possible underlying mechanisms 
One possible explanation for this observed variability in the HIP rat model would be copy loss of 
the transgene. The copy number correlates with the expression of hIAPP, therefore determining 
the timepoint of the development of the diabetic phenotype. The idea that the time point of 
development of diabetes is closely associated with the transgene copy number was proven by 
doubling the copy number by breeding homozygous transgenic mice and rats expressing hIAPP 
(Janson et al. 1996). In mice, certain hemizygous mouse models did not even develop a diabetic 
phenotype at all (Janson et al. 1996; Couce et al. 1996; Fox et al. 1993; Koning et al. 1994; Yagui 
et al. 1995) Therefore, it was hypothesized that a threshold effect is involved concerning the copy 
number and the development of a diabetic phenotype in transgenic hIAPP mice (Butler et al. 
2004). The same might apply for HIP rats. In rats, hemizygous HIP rats generally developed 
diabetes spontaneously at a later timepoint than their homozygous counterparts (Butler et al. 
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2004). In the hemizygous HIP rats (Line 9), which were used as the animal model in this study, 
the exact number of copies is not known and therefore cannot be determined and compared.  
Summarizing remarks about the variability in the HIP rat model  
The comparisons mentioned above reconfirm our observation of a delay in the progression of the 
development of T2D in our HIP rats. Further means to confirm a delay of progression would be 
to histologically analyze the β-cell content, islet amyloid and amount of bound antibody NI-
203.26C11 in the islets of the different groups. Due to the lack of progression of the diabetic 
phenotype of the HIP rats used in this study, the planed PK/PD study was postponed. The aim of 
the PK/PD study was to examine if a single administration of the antibody NI-203.26C11 could 
restore or influence β-cell function in animals with advanced diabetes. As the study was 
conducted after this dissertation was written, the results will not be presented and discussed.  
6.3. Macrophage activation as a key mechanism of action 
The second aim of this study was to investigate the role of macrophage-mediated clearance of 
hIAPP aggregates and further possible mechanisms of action. To do so, an inert LALA-PG 
version of the antibody rNI-203.26C11 was administered to examine the importance of 
macrophage mediated clearance of hIAPP aggregates. This LALA-PG NI-203.26C11 has three 
mutations in the Fcɣ domain, which prevent interaction with Fcɣ-receptors on immune cells and 
immune responses (Lo et al. 2017). The treatment with the inert LALA-PG rNI-203.26C11 
(10mg/kg) over 32 weeks resulted in an overall decrease in BW gain, FG and glucose AUC 
during the OGTT as well as an earlier decrease in FI compared to rNI-203.26C11(10mg/kg) 
treated group. These findings reflect an earlier onset of T2D, therefore supporting the idea that 
macrophage activation is a key mechanism of action of hIAPP clearance. Further, increased 
plasma IAPP levels were observed in both the 10mg/kg rNI-203.26C11 and 10mg/kg LALA-PG 
treated Tg rats, although at a later time point in the LALA-PG treated rats. This might possibly 
reflect a further, yet unknown long-term mechanism. 
Role of macrophage activation in AD 
The importance of receptor-mediated phagocytosis was also observed during the development of 
antibody-based approaches therapies for AD, for example in aducanumab (Sevigny et al. 2016). 
A previous study (Morgan 2009) gives an overview of four proposed mechanisms of inhibition of 
aggregation and removal of Aβ in AD and proposes that the extent of each mechanism depends 
on the antibody. These mechanisms include (1) catalytic dissolution, in which the process of 
aggregation is prevented by modifying secondary structure (Schenk et al. 1999; Solomon et al. 
1997; Solomon et al. 1996; Morgan 2006); (2) MHC-2 antibody-mediated phagocytosis through 
macrophages (Schenk et al. 1999; Bard et al. 2000; Webster et al. 2001; Koenigsknecht-Talboo 
and Landreth 2005; Das et al. 2003); (3) peripheral sink mechanism, in which peripheral 
circulating antibodies bind to free Aβ, resulting in increased clearance (DeMattos et al. 2001); 
and (4) FcRn mechanism, in which the facilitated transport of antibody-Aβ complexes via the 
neonatal Fc receptor is proposed (Deane et al. 2005). Due to the pathological similarities between 
Aβ aggregates in AD and hIAPP aggregates in  T2D, similar mechanisms may very well occur 
concerning antibody-mediated prevention of hIAPP aggregation and removal. As far as the FcRn 
mechanism is concerned, the expression of FcRn in interstitial and endothelial cells of the 
pancreas has yet to be determined.  
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Role of macrophage activation in T2D and AD 
In patients suffering from  T2D, an immune cell infiltration in the islets was observed often, 
mostly consisting of macrophages (Ehses et al. 2007; Richardson et al. 2009; Kamata et al. 2014; 
Martino et al. 2015). On one hand, these macrophages are thought to contribute to the 
maintenance of islet homeostasis, thus having a protective effect. On the other hand, macrophage 
activation can also lead to an increase in β-cell cytotoxicity and inflammation through cytokine 
secretion (Eguchi and Manabe 2013; Eguchi and Nagai 2017). Therefore, there is a delicate 
balance between the benefits and drawbacks of macrophage activation caused by antibody 
therapy, with yet unknown consequences. Further, it is also unknown if antibody therapy with 
rNI-203.26C11 may influence the balance between M1 and M2 macrophages. For example, in 
antibody therapy targeting Aβ in AD, some antibodies were found to induce the release of 
proinflammatory cytokines. This leads to the development of vasogenic edemas as an adverse 
reaction, contributing to amyloid-related imaging abnormalities (ARIAs) (Sperling et al. 2012; 
Sperling et al. 2011; Pankiewicz and Sadowski 2017; Carlson et al. 2011; Carlson et al. 2016; 
Arrighi et al. 2016). In comparison to the brain, less adverse effects caused by macrophage 
infiltration are to be expected in the pancreas, due to its anatomical structure and physiological 
properties. Also, no side effects were observed due to macrophage infiltration in our previous 
studies. Comparing the β-cell function of rNI-203.26C11 to its inert LALA-PG version was the 
first step to examining the impact of macrophage activation more closely. Beforehand, we 
already observed that rNI-203.26C11 recruits macrophages in HIP rat islets and stimulates the 
uptake of hIAPP aggregates following in vitro incubation. In this study, the effect of rNI-
203.26C11 (10mg/kg) on β-cell function, IAPP levels and body weight gain was compared to its’ 
inert LALA-PG version (10mg/kg).  
Influence of LALA-PG treatment in comparison to antibody-treated and PBS Tg rats 
A premature onset of loss in BW gain was observed in the LALA-PG 10mg/kg group, together 
with the 0.3mg/kg and Tg PBS group. Further, a highly significant increase in FG was observed 
in the 0.3mg/kg, LALA-PG 10mg/kg and Tg PBS groups compared to the WT PBS from the 4th 
OGTT onwards. The Tg 0.3 and 3mg/kg groups as well as the Tg PBS group already had 
decreased FI levels compared to the WT PBS from the 1st OGTT on, while this was already in the 
LALA-PG group from the 2nd OGTT on. The glucose AUC of the 0.3mg/kg, LALA-PG and Tg 
PBS groups were increased significantly compared to the WT PBS in all the OGTTs. The insulin 
AUC of the LALA-PG group was decreased significantly compared to the WT PBS together with 
almost all Tg groups in the 1st OGTT and all Tg groups in the 5th as well as 7th OGTT. Further, 
increased fasting plasma IAPP levels were observed in the LALA-PG group compared to the WT 
PBS in the 7th OGTT. This increase in fasting plasma IAPP levels might reflect both higher 
pancreatic hIAPP content or an increased elimination of hIAPP from the pancreas into the 
plasma. 
Conclusion of the role of macrophage activation 
Overall, the values of the LALA-PG treated group concerning BW gain, FG as well as glucose 
and insulin AUC were found to be comparable to those of the Tg PBS and 0.3mg/kg group. A 
somewhat later decline in FI values was observed in the LALA-PG 10mg/kg group compared to 
the Tg PBS and 0.3mg/kg groups. These findings indicate that macrophage activation plays a key 
role of all mechanisms of action concerning the clearance of toxic hIAPP aggregates. A further 
step to confirm this would be to analyze the pancreatic hIAPP and macrophage content as well as 
Discussion 
47 
 
β-cell mass and bound NI-203.26C11 in the LALA-PG treated Tg group compared to the 
10mg/kg treated Tg group. 
6.4. Development of a method of target engagement 
The third aim of this study was to develop a method for histological visualization and 
quantification of NI-203.26C11-mediated clearance of toxic hIAPP oligomers. This was achieved 
in unfixed, frozen pancreas. A diffuse extracellular occurrence of bound anti-human antibody 
was seen around insulin producing β-cells 3 days after a single i.p. injection (30mg/kg). This 
verifies that NI-203.26C11 is specific for pathogenic hIAPP oligomers and that it binds to the 
target within the islets. Also, bound anti-human antibody was only observed in the animals 
treated with hNI-203.26C11 and not in vehicle treated rats. This reconfirms the occurrence of 
bound hNI-203.26C11 in rats 3 days after injection of hNI-203.26C11. A further step would be 
the comparison to WT rats to confirm the specificity of hNI-203.26C11 to hIAPP, opposed to 
physiologically occurring rIAPP. Also, a combined counterstaining of bound antibody hNI-
203.26C11 together with a staining for islet amyloid or physiological monomeric hIAPP would 
be informative. Based on the development of this method of target engagement, a correlation 
between target engagement and drug efficacy can be examined in the future. Further, the amount 
of pathogenic hIAPP bound to the anti-human antibody could be used to quantify hIAPP 
clearance. This novel method gives us a valuable tool to visualize and quantify rNI-203.26C11 
mediated hIAPP clearance in vivo, with a broad range of application for the future. 
6.5. Conclusion 
In conclusion, the long-term application of the antibody NI-203.26C11 (1 to 10mg/kg) targeting 
toxic hIAPP oligomers in HIP rats was shown to have a protective effect on β-cell viability. 
When comparing the respective animals to the WT rats, NI-203.26C11 resulted in improved 
fasting glucose, glucose AUC during the OGTTs and prevented a loss of BW gain opposed to the 
Tg PBS rats. The effect of NI-203.26C11 was observed in the dose range from 1 to 10mg/kg, but 
within this dose range, there was no further increase in effectiveness with dose.  
This confirms that passive long-term immunotherapy with the antibody NI-203.26C11 targeting 
toxic hIAPP oligomers specifically holds great therapeutic potential. Due to the lack of 
progression of the diabetic phenotype, the data concerning the short-term efficacy of antibody 
therapy with NI-203.26C11 could not be obtained in the course of this study. The LALA-PG 
rNI.26C11 treated Tg group had similar values as the Tg PBS and 0.3mg/kg treated groups 
concerning BW gain, FG as well as glucose and insulin AUC in the OGTTs. These values 
indicate a similar extent of β-cell function between these groups, implying that macrophage 
activation is a key mechanism of action for the clearance of cytotoxic hIAPP oligomers and the 
preservation of β-cell function. A novel method of target engagement was developed and 
provides us with tool of great potential for future research.  
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